{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "9e0e84dc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "62f8a277e1d044e8bcc1e95ed53a9665",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "config.json:   0%|          | 0.00/5.00k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3b808843b5df4d4c87b82887bd33567c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "model.safetensors:   0%|          | 0.00/266M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ca339763698e4959b51f69ec69bedae4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "tokenizer_config.json:   0%|          | 0.00/373 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ce24a8849d7248caa8ebddc8f3f06803",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "vocab.txt:   0%|          | 0.00/232k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "57908322208348e4b36182824b0b08a2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "tokenizer.json:   0%|          | 0.00/711k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "398effab86304876921beb9a848b312a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "special_tokens_map.json:   0%|          | 0.00/125 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Use a pipeline as a high-level helper\n",
    "from transformers import pipeline\n",
    "\n",
    "pipe = pipeline(\"token-classification\", model=\"d4data/biomedical-ner-all\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0512ed9f",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "split = \"train.json\"\n",
    "data = json.load(open(f\"data/{split}\"))\n",
    "files = os.listdir(\"data/CT json/\")\n",
    "#files.remove(\".DS_Store\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "268b8925",
   "metadata": {},
   "outputs": [],
   "source": [
    "files_data = {file[:-5]:json.load(open(f\"data/CT json/{file}\")) for file in files}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "c5711d79",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Type</th>\n",
       "      <th>Section_id</th>\n",
       "      <th>Primary_id</th>\n",
       "      <th>Secondary_id</th>\n",
       "      <th>Statement</th>\n",
       "      <th>Label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>5bc844fc-e852-4270-bfaf-36ea9eface3d</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT01928186</td>\n",
       "      <td>NCT00684983</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "      <td>Contradiction</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86b7cb3d-6186-4a04-9aa6-b174ab764eed</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "      <td>Contradiction</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>dbed5471-c2fc-45b5-b26f-430c9fa37a37</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>NCT00093145</td>\n",
       "      <td>NCT00703326</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "      <td>Entailment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20c35c89-8d23-4be3-b603-ac0ee0f3b4de</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01097642</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "      <td>Contradiction</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>f17cb242-419d-4f5d-bfa4-41494ed5ac0e</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00852930</td>\n",
       "      <td>NCT02308020</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "      <td>Contradiction</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>f37774f4-db96-4aa6-b3a1-626953faeecf</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00213980</td>\n",
       "      <td>NCT02536339</td>\n",
       "      <td>Adequate blood, kidney, and hepatic function a...</td>\n",
       "      <td>Entailment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4fef4cdf-53bf-4239-9d31-4710fd3edc6f</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "      <td>Contradiction</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>331affb2-f8e9-4a55-ac4c-62d2ecc4f80b</th>\n",
       "      <td>Single</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00181363</td>\n",
       "      <td>NaN</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "      <td>Entailment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>a577e819-c928-4217-8743-f4809e852919</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00834678</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "      <td>Entailment</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>bd073d05-3ba2-4898-9d86-a51951a7ad1f</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01004172</td>\n",
       "      <td>NCT00802945</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "      <td>Contradiction</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1700 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                            Type      Section_id   Primary_id  \\\n",
       "5bc844fc-e852-4270-bfaf-36ea9eface3d  Comparison    Intervention  NCT01928186   \n",
       "86b7cb3d-6186-4a04-9aa6-b174ab764eed      Single     Eligibility  NCT00662129   \n",
       "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Comparison  Adverse Events  NCT00093145   \n",
       "20c35c89-8d23-4be3-b603-ac0ee0f3b4de      Single     Eligibility  NCT01097642   \n",
       "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Comparison    Intervention  NCT00852930   \n",
       "...                                          ...             ...          ...   \n",
       "f37774f4-db96-4aa6-b3a1-626953faeecf  Comparison     Eligibility  NCT00213980   \n",
       "4fef4cdf-53bf-4239-9d31-4710fd3edc6f      Single         Results  NCT01605396   \n",
       "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b      Single    Intervention  NCT00181363   \n",
       "a577e819-c928-4217-8743-f4809e852919      Single     Eligibility  NCT00834678   \n",
       "bd073d05-3ba2-4898-9d86-a51951a7ad1f  Comparison         Results  NCT01004172   \n",
       "\n",
       "                                     Secondary_id  \\\n",
       "5bc844fc-e852-4270-bfaf-36ea9eface3d  NCT00684983   \n",
       "86b7cb3d-6186-4a04-9aa6-b174ab764eed          NaN   \n",
       "dbed5471-c2fc-45b5-b26f-430c9fa37a37  NCT00703326   \n",
       "20c35c89-8d23-4be3-b603-ac0ee0f3b4de          NaN   \n",
       "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  NCT02308020   \n",
       "...                                           ...   \n",
       "f37774f4-db96-4aa6-b3a1-626953faeecf  NCT02536339   \n",
       "4fef4cdf-53bf-4239-9d31-4710fd3edc6f          NaN   \n",
       "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b          NaN   \n",
       "a577e819-c928-4217-8743-f4809e852919          NaN   \n",
       "bd073d05-3ba2-4898-9d86-a51951a7ad1f  NCT00802945   \n",
       "\n",
       "                                                                              Statement  \\\n",
       "5bc844fc-e852-4270-bfaf-36ea9eface3d  All the primary trial participants do not rece...   \n",
       "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Patients with Platelet count over 100,000/mm¬¨...   \n",
       "dbed5471-c2fc-45b5-b26f-430c9fa37a37  Heart-related adverse events were recorded in ...   \n",
       "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Adult Patients with histologic confirmation of...   \n",
       "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Laser Therapy is in each cohort of the primary...   \n",
       "...                                                                                 ...   \n",
       "f37774f4-db96-4aa6-b3a1-626953faeecf  Adequate blood, kidney, and hepatic function a...   \n",
       "4fef4cdf-53bf-4239-9d31-4710fd3edc6f  The Ridaforolimus + Dalotuzumab + Exemestane g...   \n",
       "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b  The only difference between the interventions ...   \n",
       "a577e819-c928-4217-8743-f4809e852919  Patients must have a white blood cell count ab...   \n",
       "bd073d05-3ba2-4898-9d86-a51951a7ad1f  the primary trial and the secondary trial both...   \n",
       "\n",
       "                                              Label  \n",
       "5bc844fc-e852-4270-bfaf-36ea9eface3d  Contradiction  \n",
       "86b7cb3d-6186-4a04-9aa6-b174ab764eed  Contradiction  \n",
       "dbed5471-c2fc-45b5-b26f-430c9fa37a37     Entailment  \n",
       "20c35c89-8d23-4be3-b603-ac0ee0f3b4de  Contradiction  \n",
       "f17cb242-419d-4f5d-bfa4-41494ed5ac0e  Contradiction  \n",
       "...                                             ...  \n",
       "f37774f4-db96-4aa6-b3a1-626953faeecf     Entailment  \n",
       "4fef4cdf-53bf-4239-9d31-4710fd3edc6f  Contradiction  \n",
       "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b     Entailment  \n",
       "a577e819-c928-4217-8743-f4809e852919     Entailment  \n",
       "bd073d05-3ba2-4898-9d86-a51951a7ad1f  Contradiction  \n",
       "\n",
       "[1700 rows x 6 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from collections import defaultdict as dd\n",
    "df = pd.DataFrame(data).T\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "da031d4a",
   "metadata": {},
   "outputs": [],
   "source": [
    "data_dict = {}\n",
    "\n",
    "for index, row in df.iterrows():\n",
    "    key = row['Statement']\n",
    "    value = row.drop('Statement').to_dict()\n",
    "    data_dict[f\"{key}_____{row['Label']}\"] = value\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "61266ae7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1700"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "1458a1dc",
   "metadata": {},
   "outputs": [],
   "source": [
    "hypotheses = list(df[df['Label'] == 'Entailment']['Statement'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "21e29301",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "850"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(hypotheses)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "803c91e7",
   "metadata": {},
   "outputs": [],
   "source": [
    "from types import SimpleNamespace\n",
    "\n",
    "import spacy\n",
    "from spacy import displacy\n",
    "nlp = spacy.load(\"en_core_web_sm\")\n",
    "\n",
    "def convert_to_desired_format(entity_list, text):\n",
    "    # Extracting text from the provided entities\n",
    "    #text = \" \".join([entity['word'] for entity in entity_list])\n",
    "\n",
    "    # Combining consecutive entities with the same type\n",
    "    combined_entities = []\n",
    "    current_entity = None\n",
    "\n",
    "    for entity in entity_list:\n",
    "        if entity['score'] < 0.7:\n",
    "            continue\n",
    "        if current_entity is None:\n",
    "            current_entity = {\"start\": entity['start'], \"end\": entity['end'], \"label\": entity['entity'].split('-')[-1]}\n",
    "        elif entity['entity'].split('-')[-1] == current_entity['label'] and entity['start'] in [current_entity['end'],current_entity['end']+1]:\n",
    "            current_entity['end'] = entity['end']\n",
    "        else:\n",
    "            combined_entities.append(current_entity)\n",
    "            current_entity = {\"start\": entity['start'], \"end\": entity['end'], \n",
    "                              \"label\": entity['entity'].split('-')[-1],\n",
    "                            }\n",
    "\n",
    "    if current_entity is not None:\n",
    "        combined_entities.append(current_entity)\n",
    "\n",
    "    # Creating the final output in the desired format\n",
    "    output = {\"text\": text, \"ents\": combined_entities, \"title\": None}\n",
    "    return output\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "6f173ca2",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|█████████████████████████████████████████████████████████████████████████████████████████| 850/850 [00:18<00:00, 45.40it/s]\n"
     ]
    }
   ],
   "source": [
    "from tqdm import tqdm\n",
    "res = []\n",
    "outs = []\n",
    "for text in tqdm(hypotheses):\n",
    "    ents = pipe(text)\n",
    "    \n",
    "    res.append(convert_to_desired_format(ents, text))\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "fbf4c283",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(res[19], manual=True, style='ent', jupyter=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "33c322ca",
   "metadata": {},
   "outputs": [],
   "source": [
    "outs=[]\n",
    "for out in res:\n",
    "    ents = out['ents']\n",
    "    for ent in ents:\n",
    "        ent['text'] = out['text'] \n",
    "        ent['entity'] = out['text'][ent['start']:ent['end']]\n",
    "    outs.extend(ents)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8c2803a6",
   "metadata": {},
   "source": [
    "## Entities in Hypotheses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "d475c233",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "entities = pd.DataFrame(outs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "7b7fad99",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>start</th>\n",
       "      <th>end</th>\n",
       "      <th>label</th>\n",
       "      <th>text</th>\n",
       "      <th>entity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>13</td>\n",
       "      <td>Detailed_description</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "      <td>Heart-related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>14</td>\n",
       "      <td>28</td>\n",
       "      <td>Sign_symptom</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "      <td>adverse events</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12</td>\n",
       "      <td>23</td>\n",
       "      <td>Age</td>\n",
       "      <td>Adele is an 85 year old woman with Stage II hi...</td>\n",
       "      <td>85 year old</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>24</td>\n",
       "      <td>29</td>\n",
       "      <td>Sex</td>\n",
       "      <td>Adele is an 85 year old woman with Stage II hi...</td>\n",
       "      <td>woman</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>35</td>\n",
       "      <td>43</td>\n",
       "      <td>Detailed_description</td>\n",
       "      <td>Adele is an 85 year old woman with Stage II hi...</td>\n",
       "      <td>Stage II</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2316</th>\n",
       "      <td>137</td>\n",
       "      <td>154</td>\n",
       "      <td>Diagnostic_procedure</td>\n",
       "      <td>The most common adverse event in the primary t...</td>\n",
       "      <td>Ejection fraction</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2317</th>\n",
       "      <td>14</td>\n",
       "      <td>26</td>\n",
       "      <td>Disease_disorder</td>\n",
       "      <td>Patients with cancer cells in lymph nodes abov...</td>\n",
       "      <td>cancer cells</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2318</th>\n",
       "      <td>30</td>\n",
       "      <td>62</td>\n",
       "      <td>Biological_structure</td>\n",
       "      <td>Patients with cancer cells in lymph nodes abov...</td>\n",
       "      <td>lymph nodes above the collarbone</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2319</th>\n",
       "      <td>21</td>\n",
       "      <td>43</td>\n",
       "      <td>Diagnostic_procedure</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "      <td>white blood cell count</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2320</th>\n",
       "      <td>44</td>\n",
       "      <td>61</td>\n",
       "      <td>Lab_value</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "      <td>above 1,500/mm¬¨‚</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2321 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      start  end                 label  \\\n",
       "0         0   13  Detailed_description   \n",
       "1        14   28          Sign_symptom   \n",
       "2        12   23                   Age   \n",
       "3        24   29                   Sex   \n",
       "4        35   43  Detailed_description   \n",
       "...     ...  ...                   ...   \n",
       "2316    137  154  Diagnostic_procedure   \n",
       "2317     14   26      Disease_disorder   \n",
       "2318     30   62  Biological_structure   \n",
       "2319     21   43  Diagnostic_procedure   \n",
       "2320     44   61             Lab_value   \n",
       "\n",
       "                                                   text  \\\n",
       "0     Heart-related adverse events were recorded in ...   \n",
       "1     Heart-related adverse events were recorded in ...   \n",
       "2     Adele is an 85 year old woman with Stage II hi...   \n",
       "3     Adele is an 85 year old woman with Stage II hi...   \n",
       "4     Adele is an 85 year old woman with Stage II hi...   \n",
       "...                                                 ...   \n",
       "2316  The most common adverse event in the primary t...   \n",
       "2317  Patients with cancer cells in lymph nodes abov...   \n",
       "2318  Patients with cancer cells in lymph nodes abov...   \n",
       "2319  Patients must have a white blood cell count ab...   \n",
       "2320  Patients must have a white blood cell count ab...   \n",
       "\n",
       "                                entity  \n",
       "0                        Heart-related  \n",
       "1                       adverse events  \n",
       "2                          85 year old  \n",
       "3                                woman  \n",
       "4                             Stage II  \n",
       "...                                ...  \n",
       "2316                 Ejection fraction  \n",
       "2317                      cancer cells  \n",
       "2318  lymph nodes above the collarbone  \n",
       "2319            white blood cell count  \n",
       "2320                 above 1,500/mm¬¨‚  \n",
       "\n",
       "[2321 rows x 5 columns]"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "0468e0fb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'capecitabi'"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities.loc[0]['text'][59:69]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "2d19c6d9",
   "metadata": {},
   "outputs": [],
   "source": [
    "entities_no_duplicate = entities.drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "c76e50cd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>start</th>\n",
       "      <th>end</th>\n",
       "      <th>label</th>\n",
       "      <th>text</th>\n",
       "      <th>entity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>13</td>\n",
       "      <td>Detailed_description</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "      <td>Heart-related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>14</td>\n",
       "      <td>28</td>\n",
       "      <td>Sign_symptom</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "      <td>adverse events</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12</td>\n",
       "      <td>23</td>\n",
       "      <td>Age</td>\n",
       "      <td>Adele is an 85 year old woman with Stage II hi...</td>\n",
       "      <td>85 year old</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>24</td>\n",
       "      <td>29</td>\n",
       "      <td>Sex</td>\n",
       "      <td>Adele is an 85 year old woman with Stage II hi...</td>\n",
       "      <td>woman</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>35</td>\n",
       "      <td>43</td>\n",
       "      <td>Detailed_description</td>\n",
       "      <td>Adele is an 85 year old woman with Stage II hi...</td>\n",
       "      <td>Stage II</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2316</th>\n",
       "      <td>137</td>\n",
       "      <td>154</td>\n",
       "      <td>Diagnostic_procedure</td>\n",
       "      <td>The most common adverse event in the primary t...</td>\n",
       "      <td>Ejection fraction</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2317</th>\n",
       "      <td>14</td>\n",
       "      <td>26</td>\n",
       "      <td>Disease_disorder</td>\n",
       "      <td>Patients with cancer cells in lymph nodes abov...</td>\n",
       "      <td>cancer cells</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2318</th>\n",
       "      <td>30</td>\n",
       "      <td>62</td>\n",
       "      <td>Biological_structure</td>\n",
       "      <td>Patients with cancer cells in lymph nodes abov...</td>\n",
       "      <td>lymph nodes above the collarbone</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2319</th>\n",
       "      <td>21</td>\n",
       "      <td>43</td>\n",
       "      <td>Diagnostic_procedure</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "      <td>white blood cell count</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2320</th>\n",
       "      <td>44</td>\n",
       "      <td>61</td>\n",
       "      <td>Lab_value</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "      <td>above 1,500/mm¬¨‚</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2321 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      start  end                 label  \\\n",
       "0         0   13  Detailed_description   \n",
       "1        14   28          Sign_symptom   \n",
       "2        12   23                   Age   \n",
       "3        24   29                   Sex   \n",
       "4        35   43  Detailed_description   \n",
       "...     ...  ...                   ...   \n",
       "2316    137  154  Diagnostic_procedure   \n",
       "2317     14   26      Disease_disorder   \n",
       "2318     30   62  Biological_structure   \n",
       "2319     21   43  Diagnostic_procedure   \n",
       "2320     44   61             Lab_value   \n",
       "\n",
       "                                                   text  \\\n",
       "0     Heart-related adverse events were recorded in ...   \n",
       "1     Heart-related adverse events were recorded in ...   \n",
       "2     Adele is an 85 year old woman with Stage II hi...   \n",
       "3     Adele is an 85 year old woman with Stage II hi...   \n",
       "4     Adele is an 85 year old woman with Stage II hi...   \n",
       "...                                                 ...   \n",
       "2316  The most common adverse event in the primary t...   \n",
       "2317  Patients with cancer cells in lymph nodes abov...   \n",
       "2318  Patients with cancer cells in lymph nodes abov...   \n",
       "2319  Patients must have a white blood cell count ab...   \n",
       "2320  Patients must have a white blood cell count ab...   \n",
       "\n",
       "                                entity  \n",
       "0                        Heart-related  \n",
       "1                       adverse events  \n",
       "2                          85 year old  \n",
       "3                                woman  \n",
       "4                             Stage II  \n",
       "...                                ...  \n",
       "2316                 Ejection fraction  \n",
       "2317                      cancer cells  \n",
       "2318  lymph nodes above the collarbone  \n",
       "2319            white blood cell count  \n",
       "2320                 above 1,500/mm¬¨‚  \n",
       "\n",
       "[2321 rows x 5 columns]"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities_no_duplicate"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "2b833661",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Detailed_description', 'Sign_symptom', 'Age', 'Sex',\n",
       "       'Disease_disorder', 'Biological_structure', 'Diagnostic_procedure',\n",
       "       'Therapeutic_procedure', 'Medication', 'Lab_value',\n",
       "       'Administration', 'Coreference', 'Duration', 'Severity', 'Date',\n",
       "       'Subject', 'History', 'Distance', 'Frequency',\n",
       "       'Personal_background', 'Dosage', 'Clinical_event',\n",
       "       'Quantitative_concept', 'Outcome', 'Activity', 'Family_history',\n",
       "       'Volume'], dtype=object)"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities_no_duplicate['label'].unique()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ee22d1fe",
   "metadata": {},
   "source": [
    "## Handling Numerical Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "79c894ee",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "f1994410",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'32 year old',\n",
       " '34 years',\n",
       " '51-73 years',\n",
       " '55 year old',\n",
       " '56 year old',\n",
       " '57 year old',\n",
       " '72 year old',\n",
       " '75 year old',\n",
       " '85 year old',\n",
       " 'age',\n",
       " 'age of 20',\n",
       " 'between 18-25',\n",
       " 'older',\n",
       " 'over',\n",
       " 'over the age of 18'}"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Age column\n",
    "set(entities[entities['label'] == 'Age']['entity'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "61ee61b7",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "3db10672",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial.']"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(entities[(entities['label'] == 'Age') & (entities['entity'] == 'below')]['text'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "52e3ed63",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_rows = []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "312d2f39",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "def process_age(text):\n",
    "    match = re.search(r'(\\d+) year old', text)\n",
    "    if match:\n",
    "        age = int(match.group(1))\n",
    "        new_age = age + 10\n",
    "        return re.sub(r'\\d+ year old', f'{new_age} year old', text)\n",
    "    return text\n",
    "\n",
    "old2new = dd(str)\n",
    "for text in hypotheses:\n",
    "    match = re.search(r'(\\d+) year old', text)\n",
    "    if match:\n",
    "        age = int(match.group(1))\n",
    "        new_age = age + 10\n",
    "        old2new[text] = re.sub(r'\\d+ year old', f'{new_age} year old', text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "18f9fb2b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "7"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(old2new)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "d719ec72",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(str,\n",
       "            {'Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial': 'Adele is an 95 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial',\n",
       "             'Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both the secondary trial and the primary trial.': 'Ae-Cha is a 42 year old Korean woman with an inoperable breast cancer, she is ineligible for both the secondary trial and the primary trial.',\n",
       "             'A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up.': 'A 65 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up.',\n",
       "             'A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial.': 'A 82 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial.',\n",
       "             'Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial.': 'Anna is a 67 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial.',\n",
       "             'A 56 year old patient with a masectomy would not be eligible for the primary trial': 'A 66 year old patient with a masectomy would not be eligible for the primary trial',\n",
       "             'A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial.': 'A 85 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial.'})"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "old2new"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "id": "ce865c92",
   "metadata": {},
   "outputs": [],
   "source": [
    "new_data = []\n",
    "for h, h_data in data_dict.items():\n",
    "    h, label = h.split('_____')\n",
    "\n",
    "    new_rw = dd()\n",
    "    new_rw.update(h_data)\n",
    "    new_rw['Statement'] = h\n",
    "    new_data.append(new_rw)\n",
    "    if h in old2new:\n",
    "        h_new = old2new[h]\n",
    "        new_rw = dd()\n",
    "        new_rw.update(h_data)\n",
    "        new_rw['Statement'] = h_new\n",
    "        if h_data['Label'] == 'Contradiction':\n",
    "            new_rw['Label'] = 'Entailment'\n",
    "        if h_data['Label'] == 'Entailment':\n",
    "            new_rw['Label'] = 'Contradiction'\n",
    "\n",
    "        new_data.append(new_rw)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "id": "9ba05676",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_rows.extend(new_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "id": "55d776f5",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Type</th>\n",
       "      <th>Section_id</th>\n",
       "      <th>Primary_id</th>\n",
       "      <th>Secondary_id</th>\n",
       "      <th>Label</th>\n",
       "      <th>Statement</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT01928186</td>\n",
       "      <td>NCT00684983</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>NCT00093145</td>\n",
       "      <td>NCT00703326</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01097642</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00852930</td>\n",
       "      <td>NCT02308020</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1710</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00213980</td>\n",
       "      <td>NCT02536339</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Adequate blood, kidney, and hepatic function a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1711</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1712</th>\n",
       "      <td>Single</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00181363</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1713</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00834678</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1714</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01004172</td>\n",
       "      <td>NCT00802945</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1715 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            Type      Section_id   Primary_id Secondary_id          Label  \\\n",
       "0     Comparison    Intervention  NCT01928186  NCT00684983  Contradiction   \n",
       "1         Single     Eligibility  NCT00662129          NaN  Contradiction   \n",
       "2     Comparison  Adverse Events  NCT00093145  NCT00703326     Entailment   \n",
       "3         Single     Eligibility  NCT01097642          NaN  Contradiction   \n",
       "4     Comparison    Intervention  NCT00852930  NCT02308020  Contradiction   \n",
       "...          ...             ...          ...          ...            ...   \n",
       "1710  Comparison     Eligibility  NCT00213980  NCT02536339     Entailment   \n",
       "1711      Single         Results  NCT01605396          NaN  Contradiction   \n",
       "1712      Single    Intervention  NCT00181363          NaN     Entailment   \n",
       "1713      Single     Eligibility  NCT00834678          NaN     Entailment   \n",
       "1714  Comparison         Results  NCT01004172  NCT00802945  Contradiction   \n",
       "\n",
       "                                              Statement  \n",
       "0     All the primary trial participants do not rece...  \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...  \n",
       "2     Heart-related adverse events were recorded in ...  \n",
       "3     Adult Patients with histologic confirmation of...  \n",
       "4     Laser Therapy is in each cohort of the primary...  \n",
       "...                                                 ...  \n",
       "1710  Adequate blood, kidney, and hepatic function a...  \n",
       "1711  The Ridaforolimus + Dalotuzumab + Exemestane g...  \n",
       "1712  The only difference between the interventions ...  \n",
       "1713  Patients must have a white blood cell count ab...  \n",
       "1714  the primary trial and the secondary trial both...  \n",
       "\n",
       "[1715 rows x 6 columns]"
      ]
     },
     "execution_count": 196,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(new_data).drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "1fbb4b48",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Handling Other Age samples\n",
    "map_ = {\n",
    "    'below': 'above',\n",
    "    'older': 'younger',\n",
    "    'over': 'under', \n",
    "}\n",
    "opp_map = {}\n",
    "for k, v in map_.items():\n",
    "    opp_map[k] = v\n",
    "    opp_map[v] = k"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "1a70807e",
   "metadata": {},
   "outputs": [],
   "source": [
    "old2new = dd(str)\n",
    "for text in hypotheses:\n",
    "    new_text = text\n",
    "    to_replace = []\n",
    "    for word, replacement in opp_map.items():\n",
    "        if f' {word} ' in text:\n",
    "            to_replace.append(word)\n",
    "    if len(to_replace) == 0:\n",
    "        continue\n",
    "    for word in to_replace:\n",
    "        new_text = new_text.replace(word, opp_map[word])\n",
    "\n",
    "    old2new[text] = new_text\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "48805858",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "45"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(old2new)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "dbb00023",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(str,\n",
       "            {'The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.': 'The shortest PFS in the Talazoparib group of the primary trial was under a month shorter than the Median PFS for that group.',\n",
       "             'Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.': 'Participants of the primary trial must be younger than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.',\n",
       "             'At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.': 'At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS under 9 months.',\n",
       "             'There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.': 'There was under 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.',\n",
       "             'Patients must have a life expectancy over half a year to participate in the primary trial.': 'Patients must have a life expectancy under half a year to participate in the primary trial.',\n",
       "             'the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold.': 'the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be below a certain height threshold.',\n",
       "             'Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial.': 'Females under the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial.',\n",
       "             'Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are over the age of 20.': 'Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are under the age of 20.',\n",
       "             'Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial.': 'Patients must have a confirmed Postmenopausal status, defined as a lack of menses for under a year, if they are to take part in the primary trial.',\n",
       "             'Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial.': 'Any patients with breast cancer below stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial.',\n",
       "             'The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once.': 'The intervention in the primary trial requires patients to receive multiple applications of treatment under a period of several weeks, whereas the interventions for the secondary trial are only apllied once.',\n",
       "             'Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.': 'Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or below musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.',\n",
       "             'The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months.': 'The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of under 5 months.',\n",
       "             'Patients with Platelet count over 100,000/mm¬¨‚â•, ANC <  1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial.': 'Patients with Platelet count under 100,000/mm¬¨‚â•, ANC <  1,700/mm¬¨‚â• and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial.',\n",
       "             'Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.': 'Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations above normal, the study physician can still decide to let them participate.',\n",
       "             'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.': 'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) under 3 months.',\n",
       "             'Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial.': 'Patients must be younger than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial.',\n",
       "             'The longest Time to Disease Progression the primary trial was over 11 months  in the Docetaxel Plus Capecitabine group.': 'The longest Time to Disease Progression the primary trial was under 11 months  in the Docetaxel Plus Capecitabine group.',\n",
       "             'Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months.': 'Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just over 7 and a half months.',\n",
       "             'No participants of the primary trial had a Progression Free Survival over 1 year.': 'No participants of the primary trial had a Progression Free Survival under 1 year.',\n",
       "             'A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial.': 'A female patient under the age of 18 suffering from Cirrhosis cannot take part in the primary trial.',\n",
       "             'Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.': 'Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants under 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.',\n",
       "             'Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial.': 'Females under the age of 18, whose last period was 2 weeks prior are eligible for the primary trial.',\n",
       "             'Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial.': 'Patients must be under the age of 18 and have a life expectancy under 6 months to participate in the primary trial.',\n",
       "             'Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.': 'Median (95% Confidence Interval) Progression-Free Survival (PFS) was under a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.',\n",
       "             'Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial.': 'Patients who received under 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial.',\n",
       "             'The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months.': 'The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration under 6 ng/mL under 4 months.',\n",
       "             'Patients must have an ECOG score below 3 to participate in the primary trial.': 'Patients must have an ECOG score above 3 to participate in the primary trial.',\n",
       "             'At least one participant of the primary trial survived over 200 days without documented disease progression.': 'At least one participant of the primary trial survived under 200 days without documented disease progression.',\n",
       "             'Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial': 'Female patients under 6 months pregnant cannot take part in either the secondary trial or the primary trial',\n",
       "             'The median TTP in cohort one of the primary trial is just under 27 months.': 'The median TTP in cohort one of the primary trial is just over 27 months.',\n",
       "             'One patient in the primary trial had blood calcium levels far above normal.': 'One patient in the primary trial had blood calcium levels far below normal.',\n",
       "             'Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study.': 'Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant under the course of the study.',\n",
       "             'There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial.': 'There under 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial.',\n",
       "             \"Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial.\": \"Female patients under the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial.\",\n",
       "             'In the primary trial 11.1% of patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients had Unexpected adverse events.': 'In the primary trial 11.1% of patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and under half of patients had Unexpected adverse events.',\n",
       "             'Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.': 'Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event under a span of 2 years.',\n",
       "             'There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.': 'There was under 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.',\n",
       "             'INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial.': 'INR equal to or below 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial.',\n",
       "             'In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.': 'In order to be eligible for both the secondary trial and the primary trial, patients must be female, under the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.',\n",
       "             'ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial.': 'ECOG < 2 and a life expectancy under 12 weeks are necessary to participate in the primary trial.',\n",
       "             'Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial.': 'Patients with Grade III peripheral neuropathy or below are eliminated from participation in the primary trial.',\n",
       "             '3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms.': '3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of under 30 ms.',\n",
       "             'Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial.': 'Patients with cancer cells in lymph nodes below the collarbone cannot enter the primary trial.',\n",
       "             'Patients must have a white blood cell count above 1,500/mm¬¨‚â• to participate in the primary trial.': 'Patients must have a white blood cell count below 1,500/mm¬¨‚â• to participate in the primary trial.'})"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "old2new"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "id": "34e8e60e",
   "metadata": {},
   "outputs": [],
   "source": [
    "new_data = []\n",
    "for h, h_data in data_dict.items():\n",
    "    h, label = h.split('_____')\n",
    "\n",
    "    new_rw = dd()\n",
    "    new_rw.update(h_data)\n",
    "    new_rw['Statement'] = h\n",
    "    new_data.append(new_rw)\n",
    "    if h in old2new:\n",
    "        h_new = old2new[h]\n",
    "        new_rw = dd()\n",
    "        new_rw.update(h_data)\n",
    "        new_rw['Statement'] = h_new\n",
    "        if h_data['Label'] == 'Contradiction':\n",
    "            new_rw['Label'] = 'Entailment'\n",
    "        if h_data['Label'] == 'Entailment':\n",
    "            new_rw['Label'] = 'Contradiction'\n",
    "\n",
    "        new_data.append(new_rw)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 201,
   "id": "a30a2b73",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_rows.extend(new_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 202,
   "id": "1d31a617",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Type</th>\n",
       "      <th>Section_id</th>\n",
       "      <th>Primary_id</th>\n",
       "      <th>Secondary_id</th>\n",
       "      <th>Label</th>\n",
       "      <th>Statement</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT01928186</td>\n",
       "      <td>NCT00684983</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Patients with Platelet count under 100,000/mm¬...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>NCT00093145</td>\n",
       "      <td>NCT00703326</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01097642</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1790</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1791</th>\n",
       "      <td>Single</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00181363</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1792</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00834678</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1793</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00834678</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Patients must have a white blood cell count be...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1794</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01004172</td>\n",
       "      <td>NCT00802945</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1795 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            Type      Section_id   Primary_id Secondary_id          Label  \\\n",
       "0     Comparison    Intervention  NCT01928186  NCT00684983  Contradiction   \n",
       "1         Single     Eligibility  NCT00662129          NaN  Contradiction   \n",
       "2         Single     Eligibility  NCT00662129          NaN     Entailment   \n",
       "3     Comparison  Adverse Events  NCT00093145  NCT00703326     Entailment   \n",
       "4         Single     Eligibility  NCT01097642          NaN  Contradiction   \n",
       "...          ...             ...          ...          ...            ...   \n",
       "1790      Single         Results  NCT01605396          NaN     Entailment   \n",
       "1791      Single    Intervention  NCT00181363          NaN     Entailment   \n",
       "1792      Single     Eligibility  NCT00834678          NaN     Entailment   \n",
       "1793      Single     Eligibility  NCT00834678          NaN  Contradiction   \n",
       "1794  Comparison         Results  NCT01004172  NCT00802945  Contradiction   \n",
       "\n",
       "                                              Statement  \n",
       "0     All the primary trial participants do not rece...  \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...  \n",
       "2     Patients with Platelet count under 100,000/mm¬...  \n",
       "3     Heart-related adverse events were recorded in ...  \n",
       "4     Adult Patients with histologic confirmation of...  \n",
       "...                                                 ...  \n",
       "1790  The Ridaforolimus + Dalotuzumab + Exemestane g...  \n",
       "1791  The only difference between the interventions ...  \n",
       "1792  Patients must have a white blood cell count ab...  \n",
       "1793  Patients must have a white blood cell count be...  \n",
       "1794  the primary trial and the secondary trial both...  \n",
       "\n",
       "[1795 rows x 6 columns]"
      ]
     },
     "execution_count": 202,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(new_data).drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "2b3c3418",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Administration', 'Medication', 'Diagnostic_procedure',\n",
       "       'Lab_value', 'Detailed_description', 'Sign_symptom',\n",
       "       'Biological_structure', 'Disease_disorder',\n",
       "       'Therapeutic_procedure', 'Age', 'Sex', 'Dosage', 'Duration',\n",
       "       'Coreference', 'Severity', 'History', 'Personal_background',\n",
       "       'Date', 'Subject', 'Distance', 'Frequency', 'Clinical_event',\n",
       "       'Outcome', 'Quantitative_concept', 'Activity', 'Family_history',\n",
       "       'Nonbiological_location', 'Volume'], dtype=object)"
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities_no_duplicate['label'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "831c233c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'%',\n",
       " '+ve',\n",
       " '.',\n",
       " '.5xUL',\n",
       " '/percentage',\n",
       " '0',\n",
       " '0%',\n",
       " '0.0015%',\n",
       " '0.98 cm3 increase',\n",
       " '1',\n",
       " '1 more',\n",
       " '1,700/mm¬¨‚â',\n",
       " '1,733/mm',\n",
       " '1.35',\n",
       " '1.5',\n",
       " '1/42',\n",
       " '1/7',\n",
       " '10',\n",
       " '10% higher',\n",
       " '10% more',\n",
       " '10.0',\n",
       " '10.3% higher',\n",
       " '100',\n",
       " '100,000/mm¬¨‚',\n",
       " '100,000/¬¨¬µl',\n",
       " '11',\n",
       " '11.1%',\n",
       " '11.5',\n",
       " '12',\n",
       " '120',\n",
       " '125',\n",
       " '13% lower',\n",
       " '14',\n",
       " '15',\n",
       " '15% less',\n",
       " '1500',\n",
       " '16',\n",
       " '16, 17 or 20 hours',\n",
       " '16.67% more',\n",
       " '16/179',\n",
       " '175',\n",
       " '18',\n",
       " '18% lower',\n",
       " '19.57%',\n",
       " '1cm3',\n",
       " '2',\n",
       " '2 more',\n",
       " '2 negative',\n",
       " '2 positive',\n",
       " '2.38% more',\n",
       " '2.7months',\n",
       " '2.87 cm3 decrease',\n",
       " '2/680',\n",
       " '2/93',\n",
       " '20',\n",
       " '20%',\n",
       " '20% difference',\n",
       " '20/20',\n",
       " '23',\n",
       " '25%',\n",
       " '25% more',\n",
       " '250 mg/m^2',\n",
       " '27.6%',\n",
       " '3',\n",
       " '3 mg/ks',\n",
       " '3 more',\n",
       " '3/112',\n",
       " '3/4',\n",
       " '30',\n",
       " '30%',\n",
       " '30% decrease',\n",
       " '32',\n",
       " '33% higher',\n",
       " '38% more',\n",
       " '3A',\n",
       " '3M',\n",
       " '3M1',\n",
       " '4',\n",
       " '4 million units/m^2',\n",
       " '4 more',\n",
       " '4% more',\n",
       " '40 mg/m^2',\n",
       " '5',\n",
       " '5 million units/m',\n",
       " '5 more',\n",
       " '5%',\n",
       " '5% less',\n",
       " '5,000/mm3',\n",
       " '50 x 109/l',\n",
       " '50,0000 x 109/l',\n",
       " '50kg',\n",
       " '53',\n",
       " '53.5%',\n",
       " '54',\n",
       " '55 more',\n",
       " '56.9%',\n",
       " '57',\n",
       " '57%',\n",
       " '59',\n",
       " '59%',\n",
       " '6',\n",
       " '6 mg/m2',\n",
       " '6 ng/mL',\n",
       " '60',\n",
       " '60%',\n",
       " '61 more',\n",
       " '63',\n",
       " '64',\n",
       " '66',\n",
       " '6x higher',\n",
       " '7',\n",
       " '7 more',\n",
       " '70% higher',\n",
       " '72',\n",
       " '73.0 %',\n",
       " '75.9 % change',\n",
       " '8',\n",
       " '8 more',\n",
       " '8,000/mm',\n",
       " '8,000/mm3',\n",
       " '80%',\n",
       " '80% more',\n",
       " '800',\n",
       " '82%',\n",
       " '85%',\n",
       " '89',\n",
       " '9% better',\n",
       " '90',\n",
       " '94%',\n",
       " '<',\n",
       " '< 1.2 x',\n",
       " '< 2',\n",
       " '< 2.5x',\n",
       " '< 50',\n",
       " '< 80',\n",
       " '<2',\n",
       " '<=1',\n",
       " '>',\n",
       " '> 1.6 x ULN',\n",
       " '> 50%',\n",
       " '>0',\n",
       " '>25%',\n",
       " 'Abnormal',\n",
       " 'Allred',\n",
       " 'C',\n",
       " 'Change',\n",
       " 'Complete',\n",
       " 'Complete Response',\n",
       " 'Complete response',\n",
       " 'FS',\n",
       " 'Free',\n",
       " 'Grade',\n",
       " 'Grade 1',\n",
       " 'Grade 3',\n",
       " 'Greater',\n",
       " 'High',\n",
       " 'IV',\n",
       " 'Less',\n",
       " 'Less than 0.25%',\n",
       " 'Less than 1%',\n",
       " 'Less than 1/10',\n",
       " 'Less than 1/3',\n",
       " 'Less than 1/4',\n",
       " 'Less than 10%',\n",
       " 'Less than 2% of',\n",
       " 'Less than 20',\n",
       " 'Less than 20%',\n",
       " 'Less than 30%',\n",
       " 'Less than 40%',\n",
       " 'Less than 5',\n",
       " 'Less than 5%',\n",
       " 'Less than a quarter',\n",
       " 'Less than half',\n",
       " 'Low',\n",
       " 'Lower',\n",
       " 'M',\n",
       " 'M0',\n",
       " 'More',\n",
       " 'More than',\n",
       " 'More than 1/3',\n",
       " 'More than 2',\n",
       " 'More than 2%',\n",
       " 'More than 20%',\n",
       " 'More than 5%',\n",
       " 'More than a quarter',\n",
       " 'More than half',\n",
       " 'N',\n",
       " 'Negative',\n",
       " 'Neither',\n",
       " 'No',\n",
       " 'No less than 2',\n",
       " 'No more than 1%',\n",
       " 'None',\n",
       " 'Progression',\n",
       " 'Progression-free',\n",
       " 'Response',\n",
       " 'Stage',\n",
       " 'Stage III',\n",
       " 'Survival',\n",
       " 'T',\n",
       " 'T2 N',\n",
       " 'T4 N1 M',\n",
       " 'T4 N3 M0',\n",
       " 'Triple-Negative',\n",
       " 'Twice as',\n",
       " 'Two',\n",
       " 'Type I',\n",
       " 'ZA',\n",
       " '^9',\n",
       " 'a',\n",
       " 'a quarter',\n",
       " 'abnormal',\n",
       " 'abnormally low',\n",
       " 'above 1,500/mm¬¨‚',\n",
       " 'above musculoskeletal',\n",
       " 'adverse',\n",
       " 'and a',\n",
       " 'at least 60 beats per minute',\n",
       " 'at most 50 beats per minute',\n",
       " 'below 3',\n",
       " 'below 50%',\n",
       " 'better',\n",
       " 'between 1-2',\n",
       " 'between 11 to 18 grams per deciliter',\n",
       " 'between 3-5',\n",
       " 'between 4 to 5 grams per deciliter',\n",
       " 'cal',\n",
       " 'complete',\n",
       " 'complete response',\n",
       " 'decrease',\n",
       " 'decreased',\n",
       " 'depressed',\n",
       " 'difference',\n",
       " 'different',\n",
       " 'double',\n",
       " 'el',\n",
       " 'elevated',\n",
       " 'eta',\n",
       " 'exceeding 20 degrees',\n",
       " 'exceeding 39¬¨‚',\n",
       " 'grade',\n",
       " 'grade 0',\n",
       " 'grade 3',\n",
       " 'grade 4',\n",
       " 'greater',\n",
       " 'greater than',\n",
       " 'half',\n",
       " 'high',\n",
       " 'higher',\n",
       " 'higher frequency',\n",
       " 'higher number',\n",
       " 'higher percentage',\n",
       " 'higher proportion',\n",
       " 'highest',\n",
       " 'in excess of 5 times more',\n",
       " 'increase',\n",
       " 'increased',\n",
       " 'increasing',\n",
       " 'keletal',\n",
       " 'lagen',\n",
       " 'larger',\n",
       " 'less',\n",
       " 'less than 1%',\n",
       " 'less than 1.7x',\n",
       " 'less than 1.7x UL',\n",
       " 'less than 10% higher',\n",
       " 'less than 24hrs difference',\n",
       " 'less than 3',\n",
       " 'less than 30',\n",
       " 'less than 45 kg',\n",
       " 'less than 5',\n",
       " 'less than 50%',\n",
       " 'less than 60',\n",
       " 'less than 60%',\n",
       " 'less than 9',\n",
       " 'less than a',\n",
       " 'less than a 1/3',\n",
       " 'less than a 30% difference',\n",
       " 'less than a 5% difference',\n",
       " 'less than one tenth the number',\n",
       " 'longer',\n",
       " 'longer than half a second',\n",
       " 'loss',\n",
       " 'low',\n",
       " 'lower',\n",
       " 'lower dose',\n",
       " 'lower percentage',\n",
       " 'lower percentage change',\n",
       " 'maximum',\n",
       " 'mm',\n",
       " 'more',\n",
       " 'more than',\n",
       " 'more than 1',\n",
       " 'more than 10 times',\n",
       " 'more than 2',\n",
       " 'more than 2 standard deviation',\n",
       " 'more than 2 times the upper',\n",
       " 'more than 3',\n",
       " 'more than 3 times',\n",
       " 'more than 3x',\n",
       " 'more than 5',\n",
       " 'more than 50x',\n",
       " 'more than 83% less than',\n",
       " 'more than double',\n",
       " 'mu',\n",
       " 'much lower',\n",
       " 'multiple',\n",
       " 'nary',\n",
       " 'negative',\n",
       " 'ng/',\n",
       " 'ng/ml',\n",
       " 'no',\n",
       " 'non comparable',\n",
       " 'non comparable results',\n",
       " 'none',\n",
       " 'normal',\n",
       " 'not',\n",
       " 'number',\n",
       " 'one',\n",
       " 'over',\n",
       " 'over 10% higher',\n",
       " 'partial',\n",
       " 'percentage',\n",
       " 'poor',\n",
       " 'positive',\n",
       " 'positive change',\n",
       " 'reduce',\n",
       " 'reduces',\n",
       " 'response',\n",
       " 's per',\n",
       " 'same types',\n",
       " 'shorter than',\n",
       " 'smaller Percentage Change',\n",
       " 'stage',\n",
       " 'stage 3',\n",
       " 'stage 3-4',\n",
       " 'stage 4',\n",
       " 'than',\n",
       " 'than 1 regiment',\n",
       " 'than 30%',\n",
       " 'than 5',\n",
       " 'than half',\n",
       " 'three',\n",
       " 'three or',\n",
       " 'three times',\n",
       " 'times',\n",
       " 'triple',\n",
       " 'triple negative',\n",
       " 'twice',\n",
       " 'twice as',\n",
       " 'two',\n",
       " 'und',\n",
       " 'under',\n",
       " 'upper',\n",
       " 'worse',\n",
       " 'worse results',\n",
       " 'worst',\n",
       " 'years'}"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Lab Value column\n",
    "set(entities[entities['label'] == 'Lab_value']['entity'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "3b8d49b5",
   "metadata": {},
   "outputs": [],
   "source": [
    "map_ = {\n",
    "    'increase': 'decrease',\n",
    "    'increased': 'decreased',\n",
    "    'higher': 'lower',\n",
    "    'high': 'low',\n",
    "    'more' : 'less',\n",
    "    'negative': 'positive',\n",
    "    'at least': 'at most',\n",
    "    'increasing': 'decreasing',\n",
    "    'larger': 'smaller',\n",
    "    'large': 'small',\n",
    "    'maximum': 'minimum',\n",
    "    'short': 'long',\n",
    "    'shorter': 'longer',\n",
    "    \n",
    "}\n",
    "opp_map = {}\n",
    "for k, v in map_.items():\n",
    "    opp_map[k] = v\n",
    "    opp_map[v] = k"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "a9d98d14",
   "metadata": {},
   "outputs": [],
   "source": [
    "old2new = dd(str)\n",
    "for text in hypotheses:\n",
    "    new_text = text\n",
    "    to_replace = []\n",
    "    for word, replacement in opp_map.items():\n",
    "        if f' {word} ' in text:\n",
    "            to_replace.append(word)\n",
    "    if len(to_replace) == 0:\n",
    "        continue\n",
    "    for word in to_replace:\n",
    "        new_text = new_text.replace(word, opp_map[word])\n",
    "            \n",
    "    old2new[text] = new_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "95e12f7a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "183"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(old2new)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "573c8ddd",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(str,\n",
       "            {'The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.': 'The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the Median PFS for that group.',\n",
       "             'Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.': 'Most patients in the Letrozole group of the primary trial had a increased Bone Mineral Density of the Lumbar Spine after 24 months.',\n",
       "             'One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets.': 'One patient in the primary trial had abnormally high red blood cells, white blood cells, and platelets.',\n",
       "             'In total, across both cohorts of the primary trial, there were at least 2 patients with a fever.': 'In total, across both cohorts of the primary trial, there were at most 2 patients with a fever.',\n",
       "             'Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.': 'Cohort 2 of the primary trial had one less patient with Stable disease than cohort 1.',\n",
       "             'Pre and Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy.': 'Pre and Post menopausal women can enter the primary trial, as short as they do not have prior hormone replacement therapy.',\n",
       "             'Patients with ERBB2 positive tumors are eligible for the primary trial.': 'Patients with ERBB2 negative tumors are eligible for the primary trial.',\n",
       "             'Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial.': 'Patients with invasive breast cancer with a diameter of more than 4 cm are included in the primary trial.',\n",
       "             'the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial.': 'the primary trial had a lower percentage of patients with at most partial response than either cohort of the secondary trial.',\n",
       "             'the secondary trial has more patients cohorts than the primary trial.': 'the secondary trial has less patients cohorts than the primary trial.',\n",
       "             'There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.': 'There was over 14 weeks difference in Progression-free Survival between the maximum and maximum PFS in the primary trial.',\n",
       "             'Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are over the age of 20.': 'Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as short as they are over the age of 20.',\n",
       "             'The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.': 'The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is more than 1%.',\n",
       "             'Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.': 'Although there is a much lower percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.',\n",
       "             \"Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006.\": \"Cohort 1 of the primary trial recieves more than 60% of cohort 2's dose of LA-EP2006.\",\n",
       "             'A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2.': 'A lower percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2.',\n",
       "             '59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.': '59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at most 6 months.',\n",
       "             'There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial.': 'There was more than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial.',\n",
       "             'There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial.': 'There were 4% less cases (1 less case) of Dyspnea than Dehydration in the primary trial.',\n",
       "             'There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.': 'There were less cases of embolisms in cohort 2 of the primary trial than cohort 1.',\n",
       "             'There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.': 'There were less allergic reactions observed in cohort 1 of the primary trial than cohort 2.',\n",
       "             'In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide.': 'In the primary trial Low Dose Magnesium Oxide is 400 mg/day more than low dose Magnesium Oxide.',\n",
       "             'To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.': 'To be included in the primary trial, patients must have at most 1 unidimensionally measurable lesion, and must meet some specific size conditions.',\n",
       "             'Every single patient in the primary trial experienced at least 1 adverse event.': 'Every single patient in the primary trial experienced at most 1 adverse event.',\n",
       "             'In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2.': 'In total there were less adverse events in cohort 1 of the primary trial, than in cohort 2.',\n",
       "             'None of the adverse events recorded for the primary trial occurred more than once.': 'None of the adverse events recorded for the primary trial occurred less than once.',\n",
       "             'Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.': 'Cohort 1 of the primary trial had less cases of urinary infections and lumbar fractures than cohort 2.',\n",
       "             'Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.': 'Patients in cohort 1 of the primary trial may receive gradually decreasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.',\n",
       "             'There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients.': 'There was no adverse event in cohort 2 of the primary trial which occurred in less than 5% of patients.',\n",
       "             'Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2.': 'Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 less case of Leukopenia than cohort 2.',\n",
       "             'Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.': 'Cohort 1 of the primary trial had 25% less patients experiencing adverse events than cohort 2.',\n",
       "             \"Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial.\": \"Patients' appetites were not affected in the primary trial, but at most one was affected in the secondary trial.\",\n",
       "             'Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events.': 'Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have more than 30% occurrence of adverse events.',\n",
       "             'Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial.': 'Patients must be doing more than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial.',\n",
       "             'Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine.': 'Patients in the primary trial receive a higher dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine.',\n",
       "             'the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial.': 'the primary trial had a lower occurrence rate of fistula enterovesical than the secondary trial.',\n",
       "             'There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial.': 'There were 10x less patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial.',\n",
       "             'Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.': 'Across both cohorts of the primary trial a total of two patients had high levels of oxygen in their body tissues.',\n",
       "             'There is no difference in results or cohort size between cohort 1 and 2 of the primary trial, the increase in Gy has no notable effect.': 'There is no difference in results or cohort size between cohort 1 and 2 of the primary trial, the decrease in Gy has no notable effect.',\n",
       "             'Only Black women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases.': 'Only Black women are eligible for the primary trial, as short as they do not have uncontrolled or symptomatic brain metastases.',\n",
       "             'Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and more than 30% of those in cohort 2 of the secondary trial had adverse events.': 'Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and less than 30% of those in cohort 2 of the secondary trial had adverse events.',\n",
       "             'Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.': 'Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are less than 2 standard deviations below normal, the study physician can still decide to let them participate.',\n",
       "             'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.': 'One patient in the primary trial had a 2.87 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months.',\n",
       "             'There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but less cases of Febrile neutropenia than Neutropenia.': 'There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but more cases of Febrile neutropenia than Neutropenia.',\n",
       "             'the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.': 'the primary trial recorded more seizures than the secondary trial, despite having more than one tenth the number of patients in its total cohort.',\n",
       "             'The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort.': 'The Triple-Negative Breast Cancer cohort of the primary trial had a much higher ORR than the HR+/HER2- cohort.',\n",
       "             'Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, as long as they do not have uncontrolled Hypertension.': 'Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, as short as they do not have uncontrolled Hypertension.',\n",
       "             'The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month.': 'The difference in median, maximum and maximum Overall Survival (OS) of Patients between the two cohort of the primary trial was more than one month.',\n",
       "             'Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr).': 'Both cohorts of the primary trial in a positive (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr).',\n",
       "             'For all adverse event types in the primary trial, at least one case was recorded.': 'For all adverse event types in the primary trial, at most one case was recorded.',\n",
       "             'Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial.': 'Patients must be older than 18, female, have one or less target lesions and less than 2 regiments of chemotherapy to participate in the primary trial.',\n",
       "             'The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial.': 'The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was higher than the median time for patients in the secondary trial.',\n",
       "             'The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial, compared to cohort 2.': 'The Median time from randomization to death due to any cause was lower in cohort 1 of the primary trial, compared to cohort 2.',\n",
       "             'There were more cases of deteriorating mental health in the primary trial than the secondary trial.': 'There were less cases of deteriorating mental health in the primary trial than the secondary trial.',\n",
       "             'Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial': 'Patients do not need to have a Her2neu negative tumours or a measurable indicator lesion to be included in the primary trial',\n",
       "             'Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months.': 'Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of less than 3 months.',\n",
       "             'Participants of the primary trial must undergo at least one MRI during the intervention, in the secondary trial patients must use a fitbit.': 'Participants of the primary trial must undergo at most one MRI during the intervention, in the secondary trial patients must use a fitbit.',\n",
       "             'In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.': 'In the primary trial There was more than 3 days difference between the minimum recorded TTP of the Exemestane group and the Anastrozole group.',\n",
       "             'Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort.': 'Group 1 of the secondary trial has a lower ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort.',\n",
       "             'Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial.': 'Patients with aspartate aminotransferase less than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial.',\n",
       "             'Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial.': 'Skin infections were less common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial.',\n",
       "             'The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group': 'The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival less than 2 months longer than the Carboplatin group',\n",
       "             'In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. ': 'In the primary trial a cohort 1 has a lower percentage of patients with progression free survival at 3 months after treatment, than cohort 2. ',\n",
       "             'the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts.': 'the secondary trial reported less cases of Haematemesis, but the primary trial had less total cases of DIASTOLIC DYSFUNCTION across both its cohorts.',\n",
       "             'the primary trial recorded 2.38% more total adverse events than the secondary trial': 'the primary trial recorded 2.38% less total adverse events than the secondary trial',\n",
       "             'Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.': 'Participants in cohort 1 of the primary trial weighing more than 45 kg receive 4 million units/m^2 more of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.',\n",
       "             'Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally.': 'Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a lower % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally.',\n",
       "             'Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.': 'Abraxane + Tigatuzumab group of the primary trial has 10% less patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at most a 30% increase in the sum of the longest diameter of target lesions than the Abraxane Alone group.',\n",
       "             'Cohort 1 of the primary trial had a longer median, maximum and minimum pfs than cohort 2.': 'Cohort 1 of the primary trial had a shorter median, maximum and maximum pfs than cohort 2.',\n",
       "             'the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD).': 'the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for decreasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD).',\n",
       "             'The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191.': 'The maximum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191.',\n",
       "             'There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.': 'There was more than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.',\n",
       "             'In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia.': 'In the primary trial cohort 2 had less patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had less than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia.',\n",
       "             'Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis.': 'Participants of the primary trial less Imatinib mesylate than Letrozole on a daily basis.',\n",
       "             'The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels.': 'The most common adverse event in cohort 1 of the primary trial is high Hemoglobin levels.',\n",
       "             'Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.': 'Cohort 2 of the primary trial receives lower doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.',\n",
       "             'Only patients with HER2 positive breast carcinoma are eligible for the primary trial.': 'Only patients with HER2 negative breast carcinoma are eligible for the primary trial.',\n",
       "             'Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the secondary trial.': 'Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be more than 1.7x ULN. These conditions are not explicitly required for the secondary trial.',\n",
       "             'the primary trial more than 6 different types of cardiac related adverse events.': 'the primary trial less than 6 different types of cardiac related adverse events.',\n",
       "             'the secondary trial has a much longer duration than the primary trial.': 'the secondary trial has a much shorter duration than the primary trial.',\n",
       "             'Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.': 'Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month lower for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.',\n",
       "             'Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.': 'Spanish women with a heart rate of at most 60 beats per minute are eligible for the primary trial.',\n",
       "             'Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.': 'Arm 1 of the primary trial receive dose-intensive chemotherapy on a week short cycle up to 12 times in the absence of disease progression or unacceptable toxicity.',\n",
       "             'Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.': 'Cohort 1 of the primary trial recorded less instances of Neutropenic fever than Cohort 1 of the secondary trial.',\n",
       "             'compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2. ': 'compared to cohort 1 of the primary trial, there are less cases of every observed adverse event in cohort 2. ',\n",
       "             'There is only 1 adverse event in the primary trial that occurred more than once.': 'There is only 1 adverse event in the primary trial that occurred less than once.',\n",
       "             'The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group.': 'The Herceptin group in the primary trial had a lower number of Patients Achieving Pathological Complete Response than the CT-P6 group.',\n",
       "             'In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients. Whereas all the primary trial participants receive the same treatment.': 'In the secondary trial Her-2 neu negative breast cancer patients receive additional maintenance therapy  compared to other patients. Whereas all the primary trial participants receive the same treatment.',\n",
       "             'the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.': 'the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was more than a 30% difference in DFS rate between the two cohorts.',\n",
       "             'the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate.': 'the primary trial patients are administered 6-Mercaptopurine less often and in lower dosages than Methotrexate.',\n",
       "             'One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.': 'One patient in the primary trial experienced a thromboembolic event, a condition associated with a low degree of morbidity and mortality. However, the most common adverse event was Diarrhea.',\n",
       "             'Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines.': 'Neither cohort of the primary trial need to perform high intensity exercise prior to each cycle of anthracyclines.',\n",
       "             'Patients in the control group of the primary trial had a median Overall Survival of less than a year.': 'Patients in the control group of the primary trial had a median Overall Survival of more than a year.',\n",
       "             'the primary trial and the secondary trial share at least one drug in their chemotherapy regiment.': 'the primary trial and the secondary trial share at most one drug in their chemotherapy regiment.',\n",
       "             'Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial.': 'Only two types of adverse events occurred in less than 1% of patient in cohort 1 of the primary trial.',\n",
       "             'Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole.': 'Cohort 2 of the primary trial recieves a higher dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole.',\n",
       "             'There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in the secondary trial than in the primary trial': 'There are less cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in the secondary trial than in the primary trial',\n",
       "             'The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group.': 'The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the minimum PFS was in the Abiraterone Acetate + Prednisone group.',\n",
       "             'The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.': 'The placebo group in the primary trial had a much higher Median PFS than the MM-121 cohort.',\n",
       "             'There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1.': 'There were 5 less cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1.',\n",
       "             'The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months.': 'The Ultra-rapid Metabolizers group of the primary trial had average decrease of Endoxifen Concentration over 6 ng/mL over 4 months.',\n",
       "             'Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2.': 'Cohorts 1 of the primary trial recieves Bevacizumab at a lower frequency than cohort 2.',\n",
       "             'Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial.': 'Patients with a negative FISH result are eligible for the secondary trial, but not for the primary trial.',\n",
       "             'the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.': 'the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may decrease OS, compared to Capecitabine alone.',\n",
       "             'There were no adverse event in the primary trial which occurred more than 71 times.': 'There were no adverse event in the primary trial which occurred less than 71 times.',\n",
       "             '30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment.': '30% of the primary trial participants had an decreased level of CECs after 3 weeks of Cediranib Maleate treatment.',\n",
       "             'the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial.': 'the primary trial had a higher total percentage of patients experiencing adverse events compared to the secondary trial.',\n",
       "             'All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial.': 'All cohorts in the primary trial had higher percentage of participants with pCR compared to cohort 1 of the secondary trial.',\n",
       "             'A higher percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial.': 'A lower percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial.',\n",
       "             'Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily.': 'Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD less than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily.',\n",
       "             'the secondary trial recorded more cardiac related adverse events than the primary trial.': 'the secondary trial recorded less cardiac related adverse events than the primary trial.',\n",
       "             'In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.': 'In total cohort 1 of the primary trial recorded less than 10 times the number of adverse events as cohort 2.',\n",
       "             'Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks.': 'Patients in the primary trial receive at most 150mg of IMGN853 by IV every 3 weeks.',\n",
       "             'The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.': 'The Percentage of Participants With Feasibility was 10% lower in cohort 1 of the primary trial than in cohort 2.',\n",
       "             'Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.': 'Patients in the primary trial treated with Fulvestrant 250 mg had a lower Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.',\n",
       "             'There were more cases of Anemia and vomiting in the primary trial than the secondary trial.': 'There were less cases of Anemia and vomiting in the primary trial than the secondary trial.',\n",
       "             'the primary trial treament last for a shorter period of time than the secondary trial treatment.': 'the primary trial treament last for a longer period of time than the secondary trial treatment.',\n",
       "             'Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once.': 'Only 2 of the 12 adverse event types recorded in the primary trial, occurred less than once.',\n",
       "             'There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.': 'There were less patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.',\n",
       "             'Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study.': 'Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant over the course of the study.',\n",
       "             'The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.': 'The difference between cohort 1 and 2 of the primary trial is the insertion of an additional positive pressure drain for patients in cohort 2.',\n",
       "             'Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan.': 'Patients in cohort 1 of the primary trial receive Exemestane less often than cohort 2 patients receive Cytoxan.',\n",
       "             'Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%.': 'Both patient cohorts of the primary trial had a median Insulin change from baseline higher than -15%.',\n",
       "             'the primary trial has a 5 year long intervention, the duration of the secondary trial is not specified in the intervention section.': 'the primary trial has a 5 year short intervention, the duration of the secondary trial is not specified in the intervention section.',\n",
       "             'In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 recieves more than double the dose of cohort 1.': 'In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 recieves less than double the dose of cohort 1.',\n",
       "             'Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.': 'Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at most 24 weeks.',\n",
       "             'There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case.': 'There were 6 adverse event categories for cohort 1 of the primary trial which recorded at most one case.',\n",
       "             'Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial.': 'Patients with a negative sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial.',\n",
       "             'Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2.': 'Febrile neutropenia was in excess of 5 times less common in cohort 1 of the primary trial, than in cohort 2.',\n",
       "             'More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells.': 'More than 3 patients in the primary trial suffered from adverse events associated with a high number of white blood cells.',\n",
       "             'Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet.': 'Any patient can enter into the primary trial as short as they are willing to provide Informed consent and are capable of using the internet.',\n",
       "             'the primary trial recorded less patients with nausea than the secondary trial.': 'the primary trial recorded more patients with nausea than the secondary trial.',\n",
       "             'Elizabeth has HER2 positive breast cancer, she is eligible for the primary trial.': 'Elizabeth has HER2 negative breast cancer, she is eligible for the primary trial.',\n",
       "             '60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.': '60% of Subjects in the primary trial were able to Complete at most 85% of the Planned Dose on Schedule.',\n",
       "             'There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.': 'There were 5 less cases of Anaemia and 1 less case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.',\n",
       "             'Throughout the duration of the primary trial, pariticpants receive tipifarnib more often than Fulvestrant.': 'Throughout the duration of the primary trial, pariticpants receive tipifarnib less often than Fulvestrant.',\n",
       "             'Patients with tumors that are HER2 negative, PR and ER positive are eligible for the primary trial.': 'Patients with tumors that are HER2 negative, PR and ER negative are eligible for the primary trial.',\n",
       "             'A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial.': 'A lower number of patients in the secondary trial suffured from infection compared to those in the primary trial.',\n",
       "             'A minimum bodyweight of 50kg is required to participate in the primary trial.': 'A maximum bodyweight of 50kg is required to participate in the primary trial.',\n",
       "             'the secondary trial recorded more total occurences of cardiac adverse events than the primary trial.': 'the secondary trial recorded less total occurences of cardiac adverse events than the primary trial.',\n",
       "             'The total number of patients affected by adverse events in cohort 2 the primary trial, is larger than the cohort size of the secondary trial.': 'The total number of patients affected by adverse events in cohort 2 the primary trial, is smaller than the cohort size of the secondary trial.',\n",
       "             'In total there were more adverse events in the secondary trial than in the primary trial.': 'In total there were less adverse events in the secondary trial than in the primary trial.',\n",
       "             'Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial.': 'Patients must have at most 1 prior treatment with trastuzumab to be eligible for the primary trial.',\n",
       "             'Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial.': 'Cohort 1 of the secondary trial had less than 3x the cohort size of cohort 1 of the primary trial.',\n",
       "             'Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial.': 'Cohort 1 of the secondary trial recorded less cases of diarrhea and dyspepsia than cohort 1 of the primary trial.',\n",
       "             'Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial.': 'Cohort 1 of the primary trial 15% more total adverse events than cohort 2 of the secondary trial.',\n",
       "             'Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial.': 'Patients with HER2 positive BC are eligible for both the primary trial and the secondary trial.',\n",
       "             'Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.': 'Cohort 1 of the primary trial recorded less white blood cell related adversse events than cohort 2.',\n",
       "             'Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.': 'Every patient in the primary trial suffered at most 1 Treatment-emergent adverse event over a span of 2 years.',\n",
       "             'The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients.': 'The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 1% of patients.',\n",
       "             'There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.': 'There was over 10% less cases of adverse events in cohort 2 than in cohort 1 of the primary trial.',\n",
       "             'A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial.': 'A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of less than a year would be eligible for the primary trial.',\n",
       "             'In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.': 'In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% higher than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.',\n",
       "             'In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.': 'In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 positive breast cancer.',\n",
       "             'the primary trial has a shorter time frame than the secondary trial.': 'the primary trial has a longer time frame than the secondary trial.',\n",
       "             'There is no maximum or minimum age defined for participation in the primary trial or the secondary trial.': 'There is no maximum or maximum age defined for participation in the primary trial or the secondary trial.',\n",
       "             'Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.': 'Cohort 1 of the primary trial had a much lower mortality rate than cohort 2.',\n",
       "             'the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.': 'the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival less than 2 months shorter than patients administered with Lapatinib Plus Capecitabine.',\n",
       "             'The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial.': 'The Median Overall Survival for cohort 1 patients was 44 days shorter than for patients in cohort 2 of the primary trial.',\n",
       "             'The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group': 'The Single IV Infusion of ZA 4 mg group of the primary trial had a larger Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group',\n",
       "             'Both the primary trial and the secondary trial at least partly administer their interventions intravenously.': 'Both the primary trial and the secondary trial at most partly administer their interventions intravenously.',\n",
       "             'In total more participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response.': 'In total less participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response.',\n",
       "             'the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group.': 'the percentage of participants achieving complete response (CR) or partial response (PR) was much higher in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group.',\n",
       "             'the primary trial recorded less than 5 different Adverse Events .': 'the primary trial recorded more than 5 different Adverse Events .',\n",
       "             'Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial.': 'Gastrointestinal haemorrhage was less common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial.',\n",
       "             'In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial.': 'In total the secondary trial recorded only 1 less case of Mucosal inflammation than the primary trial.',\n",
       "             'Patients with a QT interval longer than half a second are excluded from the primary trial.': 'Patients with a QT interval shorter than half a second are excluded from the primary trial.',\n",
       "             'the primary trial participants receive more anastrozole, letrozole and exemestane than patients in the secondary trial.': 'the primary trial participants receive less anastrozole, letrozole and exemestane than patients in the secondary trial.',\n",
       "             ' Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial.': ' Patients with metastasis in four or less axillary lymph nodes are eligible for the primary trial.',\n",
       "             'The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months.': 'The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months.',\n",
       "             'The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.': 'The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at most Near Complete Pathologic Response, or better, after 12 weeks.',\n",
       "             'Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.': 'Participants of cohort 1 in the primary trial received less Dasatinib than those in cohort 2.',\n",
       "             'Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.': 'Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as short as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.',\n",
       "             'Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial.': 'Patients with HER2 negative breast tumors are eligible for the primary trial and the secondary trial.',\n",
       "             'Patients with ER positive, PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial.': 'Patients with ER negative, PR negative or HER2 negative tumors may be eligible for the secondary trial or the primary trial.',\n",
       "             'Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.': 'Intervention 2 of the primary trial resulted in a higher percentage in Mammographic Density than intervention 1.',\n",
       "             'The duration of treatment in the primary trial is half as long as in the secondary trial.': 'The duration of treatment in the primary trial is half as short as in the secondary trial.',\n",
       "             'No more than 1% of either cohorts of the primary trial felt nauseous.': 'No less than 1% of either cohorts of the primary trial felt nauseous.',\n",
       "             'On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density.': 'On average cohort 1 participants in the primary trial had an decreased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density.',\n",
       "             'Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.': 'Best Overall Response (BOR) was more than 10% lower in cohort 1 of the primary trial than in cohort 2.',\n",
       "             'Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects.': 'Neither of the cohorts in the primary trial had less than 5% of patients experiencing side effects.',\n",
       "             'Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.': 'Cohort 2 of the primary trial receive a lower dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.',\n",
       "             'The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).': 'The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a increase in Ejection fraction (4.95%).'})"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "old2new"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 206,
   "id": "8a873218",
   "metadata": {},
   "outputs": [],
   "source": [
    "new_data = []\n",
    "for h, h_data in data_dict.items():\n",
    "    h, label = h.split('_____')\n",
    "\n",
    "    new_rw = dd()\n",
    "    new_rw.update(h_data)\n",
    "    new_rw['Statement'] = h\n",
    "    new_data.append(new_rw)\n",
    "    if h in old2new:\n",
    "        h_new = old2new[h]\n",
    "        new_rw = dd()\n",
    "        new_rw.update(h_data)\n",
    "        new_rw['Statement'] = h_new\n",
    "        if h_data['Label'] == 'Contradiction':\n",
    "            new_rw['Label'] = 'Entailment'\n",
    "        if h_data['Label'] == 'Entailment':\n",
    "            new_rw['Label'] = 'Contradiction'\n",
    "\n",
    "        new_data.append(new_rw)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "id": "431fbf43",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_rows.extend(new_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "id": "532cc782",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Type</th>\n",
       "      <th>Section_id</th>\n",
       "      <th>Primary_id</th>\n",
       "      <th>Secondary_id</th>\n",
       "      <th>Label</th>\n",
       "      <th>Statement</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT01928186</td>\n",
       "      <td>NCT00684983</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>NCT00093145</td>\n",
       "      <td>NCT00703326</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01097642</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00852930</td>\n",
       "      <td>NCT02308020</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2087</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00213980</td>\n",
       "      <td>NCT02536339</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Adequate blood, kidney, and hepatic function a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2088</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2089</th>\n",
       "      <td>Single</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00181363</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2090</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00834678</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2091</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01004172</td>\n",
       "      <td>NCT00802945</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2092 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            Type      Section_id   Primary_id Secondary_id          Label  \\\n",
       "0     Comparison    Intervention  NCT01928186  NCT00684983  Contradiction   \n",
       "1         Single     Eligibility  NCT00662129          NaN  Contradiction   \n",
       "2     Comparison  Adverse Events  NCT00093145  NCT00703326     Entailment   \n",
       "3         Single     Eligibility  NCT01097642          NaN  Contradiction   \n",
       "4     Comparison    Intervention  NCT00852930  NCT02308020  Contradiction   \n",
       "...          ...             ...          ...          ...            ...   \n",
       "2087  Comparison     Eligibility  NCT00213980  NCT02536339     Entailment   \n",
       "2088      Single         Results  NCT01605396          NaN  Contradiction   \n",
       "2089      Single    Intervention  NCT00181363          NaN     Entailment   \n",
       "2090      Single     Eligibility  NCT00834678          NaN     Entailment   \n",
       "2091  Comparison         Results  NCT01004172  NCT00802945  Contradiction   \n",
       "\n",
       "                                              Statement  \n",
       "0     All the primary trial participants do not rece...  \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...  \n",
       "2     Heart-related adverse events were recorded in ...  \n",
       "3     Adult Patients with histologic confirmation of...  \n",
       "4     Laser Therapy is in each cohort of the primary...  \n",
       "...                                                 ...  \n",
       "2087  Adequate blood, kidney, and hepatic function a...  \n",
       "2088  The Ridaforolimus + Dalotuzumab + Exemestane g...  \n",
       "2089  The only difference between the interventions ...  \n",
       "2090  Patients must have a white blood cell count ab...  \n",
       "2091  the primary trial and the secondary trial both...  \n",
       "\n",
       "[2092 rows x 6 columns]"
      ]
     },
     "execution_count": 208,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(new_data).drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "id": "49ecef38",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Administration', 'Medication', 'Diagnostic_procedure',\n",
       "       'Lab_value', 'Detailed_description', 'Sign_symptom',\n",
       "       'Biological_structure', 'Disease_disorder',\n",
       "       'Therapeutic_procedure', 'Age', 'Sex', 'Dosage', 'Duration',\n",
       "       'Coreference', 'Severity', 'History', 'Personal_background',\n",
       "       'Date', 'Subject', 'Distance', 'Frequency', 'Clinical_event',\n",
       "       'Outcome', 'Quantitative_concept', 'Activity', 'Family_history',\n",
       "       'Nonbiological_location', 'Volume'], dtype=object)"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities_no_duplicate['label'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "3445395a",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'0.05',\n",
       " '1',\n",
       " '1 milligram',\n",
       " '10 minutes',\n",
       " '100 mg',\n",
       " '1000 mg PO daily',\n",
       " '1000mg daily',\n",
       " '120 mg',\n",
       " '12mg Q',\n",
       " '145 mg/m¬¨',\n",
       " '150',\n",
       " '150 mg/Day',\n",
       " '1500 mg',\n",
       " '1500 mg PO',\n",
       " '1500 milligrams',\n",
       " '150mg',\n",
       " '150mg once every 4 weeks',\n",
       " '160 mg',\n",
       " '2',\n",
       " '2 weeks',\n",
       " '200 milligrams (',\n",
       " '200mg',\n",
       " '21 day cycles',\n",
       " '25 mg/meter^2',\n",
       " '250',\n",
       " '250 mg',\n",
       " '250mg',\n",
       " '28',\n",
       " '28 day',\n",
       " '2mg/kg',\n",
       " '3 doses',\n",
       " '3 ml Perflut',\n",
       " '3 times per',\n",
       " '3 times per week',\n",
       " '3.25 mg',\n",
       " '30',\n",
       " '30 mg',\n",
       " '300 mg',\n",
       " '30mg',\n",
       " '4',\n",
       " '4 mg',\n",
       " '4 mg Delayed',\n",
       " '4 mg/',\n",
       " '40 mg',\n",
       " '40 mg/m2',\n",
       " '40 mg/m^2',\n",
       " '40 milligram',\n",
       " '40 milligrams',\n",
       " '40.5 Gy',\n",
       " '400 mg/day',\n",
       " '40mg PO',\n",
       " '4mg/kg',\n",
       " '5 doses',\n",
       " '5 mg group',\n",
       " '50 mg',\n",
       " '500mg',\n",
       " '50mg',\n",
       " '50mg/',\n",
       " '50mg/m2',\n",
       " '6',\n",
       " '6 mg',\n",
       " '6 tablets',\n",
       " '60 mg',\n",
       " '600 mg',\n",
       " '600 mg/m2',\n",
       " '70',\n",
       " '750mg',\n",
       " '75mg/m2',\n",
       " '800',\n",
       " '800mg',\n",
       " '80mg/m2',\n",
       " 'High',\n",
       " 'High Dose',\n",
       " 'Low',\n",
       " 'Low Dose',\n",
       " 'QD',\n",
       " 'Twice Daily',\n",
       " 'cycles',\n",
       " 'daily',\n",
       " 'daily dose',\n",
       " 'dose',\n",
       " 'doses',\n",
       " 'duration of cycles',\n",
       " 'every',\n",
       " 'every month',\n",
       " 'higher dos',\n",
       " 'higher dosages',\n",
       " 'higher doses',\n",
       " 'ig',\n",
       " 'less mg',\n",
       " 'mg',\n",
       " 'more mg',\n",
       " 'once',\n",
       " 'once daily',\n",
       " 'recieves',\n",
       " 'twice',\n",
       " 'twice a month',\n",
       " 'twice daily',\n",
       " 'weekly'}"
      ]
     },
     "execution_count": 95,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Lab Value column\n",
    "set(entities[entities['label'] == 'Dosage']['entity'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "id": "2a5fdf93",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily.',\n",
       " 'the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily.']"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(entities[(entities['label'] == 'Dosage') & (entities['entity'] == '6 tablets')]['text'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "4fc41467",
   "metadata": {},
   "outputs": [],
   "source": [
    "values_to_perturb = {\n",
    "    '1 milligram': '10 milligrams',\n",
    "    '10 minutes': '20 minutes',\n",
    "    '100 mg': '200 mg',\n",
    "    '1000 mg PO daily': '2000 mg PO daily',\n",
    "    '150 mg/Day': '300 mg/Day',\n",
    "    '1500 mg': '3000 mg',\n",
    "    '150mg': '300mg',\n",
    "    '150mg once every 4 weeks': '300mg once every 4 weeks',\n",
    "    '2 weeks': '3 weeks',\n",
    "    '200 milligrams (': '400 milligrams (',\n",
    "    '200mg': '400mg',\n",
    "    '21 day cycles': '42 day cycles',\n",
    "    '25 mg/meter^2': '50 mg/meter^2',\n",
    "    '250': '500',\n",
    "    '250 mg': '500 mg',\n",
    "    '250mg': '500mg',\n",
    "    '28 day': '15 day',\n",
    "    '2mg/kg': '3mg/kg',\n",
    "    '3 doses': '4 doses',\n",
    "    '3 ml Perflut': '4 ml Perflut',\n",
    "    '3 times per': '4 times per',\n",
    "    '3 times per week': '4 times per week',\n",
    "    '3.25 mg': '6.5 mg',\n",
    "    '4 mg Delayed': '8 mg Delayed',\n",
    "    '4 mg/': '8 mg/',\n",
    "    '40 mg': '80 mg',\n",
    "    '40 mg/m2': '80 mg/m2',\n",
    "    '40 mg/m^2': '80 mg/m^2',\n",
    "    '40 milligram': '80 milligram',\n",
    "    '40 milligrams': '80 milligrams',\n",
    "    '40.5 Gy': '81 Gy',\n",
    "    '400 mg/day': '800 mg/day',\n",
    "    '40mg PO': '80mg PO',\n",
    "    '4mg/kg': '8mg/kg',\n",
    "    '5 doses': '6 doses',\n",
    "    '5 mg group': '10 mg group',\n",
    "    '50 mg': '100 mg',\n",
    "    '500mg': '1000mg',\n",
    "    '50mg': '100mg',\n",
    "    '50mg/': '100mg/',\n",
    "    '50mg/m2': '100mg/m2',\n",
    "    '6 mg': '7 mg',\n",
    "    '6 tablets': '8 tablets',\n",
    "    '60 mg': '80 mg',\n",
    "    '600 mg': '800 mg',\n",
    "    '600 mg/m2': '1200 mg/m2',\n",
    "    '750mg': '1500mg',\n",
    "    '75mg/m2': '150mg/m2',\n",
    "    '800mg': '900mg',\n",
    "    '80mg/m2': '90mg/m2',\n",
    "    'once': 'twice',\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "1bf6261f",
   "metadata": {},
   "outputs": [],
   "source": [
    "old2new = dd(str)\n",
    "for text in hypotheses:\n",
    "    new_text = text\n",
    "    to_replace = []\n",
    "    for word, replacement in values_to_perturb.items():\n",
    "        if f' {word} ' in text:\n",
    "            to_replace.append(word)\n",
    "    if len(to_replace) == 0:\n",
    "        continue\n",
    "    for word in to_replace:\n",
    "        new_text = new_text.replace(word, values_to_perturb[word])\n",
    "            \n",
    "    old2new[text] = new_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "d4237166",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "33"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(old2new)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "e8c6a7ed",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(str,\n",
       "            {'At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.': 'At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 80 milligram (mg) twice daily and weekly 20 minutes intravenous infusions of Vinorelbine 50 mg/meter^2 (meter=m) had a PFS over 9 months.',\n",
       "             'A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial.': 'A patient who underwent T-cell transfer therapy in the past 3 weeks would be excluded from the primary trial.',\n",
       "             'Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily.': 'Intervention 1 of the primary trial require participants to take 300 mg alpelisib twice daily.',\n",
       "             'In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide.': 'In the primary trial Low Dose Magnesium Oxide is 800 mg/day less than high dose Magnesium Oxide.',\n",
       "             'Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.': 'Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 80mg PO to 100mg PO.',\n",
       "             ' Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.': ' Patients in the primary trial receive oral pazopanib twice daily every day, continuing until disease progression or unacceptable toxicity.',\n",
       "             'All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.': 'All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 100 mg With Letrozole group.',\n",
       "             'Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.': 'Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy twice every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.',\n",
       "             'participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD.': 'participants of cohort 1 in the primary trial and all participants of the secondary trial take 10 milligrams of anastrozole PO QD.',\n",
       "             'Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month.': 'Patients in the primary trial receive 6 doses of Azacitidine (Vidaza) every month and 4 doses of Nab-paclitaxel (Abraxane) per month.',\n",
       "             'the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle.': 'the primary trial participants apply topical imiquimod to cutaneous lesions twice daily on days for a total of 13 days every 15 day cycle.',\n",
       "             'Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.': 'Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 4 times per week for 6 doses.',\n",
       "             'Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally.': 'Participants in the primary trial administered with Fulvestrant 1000mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 900mg of Venetoclax orally.',\n",
       "             'Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial.': 'Females over the age of 18, whose last period was 3 weeks prior are eligible for the primary trial.',\n",
       "             'the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic).': 'the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 8 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic).',\n",
       "             'the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles': 'the primary trial Participants received niraparib 200 milligrams (mg) PO twice daily for a 15 day cycle, for 2 cycles',\n",
       "             'cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily.': 'cohort 1 of the primary trial recieves 80 mg of Ginkgo Biloba twice daily.',\n",
       "             '56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.': '56.9% of the primary trial subjects treated with Lapatinib 3000 mg had no progressive Disease at Week 12.',\n",
       "             'the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily.': 'the primary trial participants must take 8 tablets of Lapatinib Monotherapy (250mg) PO twice daily.',\n",
       "             'Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever.': 'Only patients in the primary trial receive 81 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever.',\n",
       "             'the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.': 'the primary trial results suggest that 80 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.',\n",
       "             'The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17': 'The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 80 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17',\n",
       "             'Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily.': 'Cohort 2 subjects of the primary trial receive 6.5 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily.',\n",
       "             'Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks.': 'Patients in the primary trial receive at least 300mg of IMGN853 by IV every 3 weeks.',\n",
       "             'Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.': 'Patients in the primary trial treated with Fulvestrant 500 mg had a higher Objective response rate than those treated with Fulvestrant 500 mg + Loading Dose.',\n",
       "             'Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.': 'Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 3 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.',\n",
       "             'The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.': 'The Ixabepilone 80 mg/m^2 group in the primary trial reported worse results than the Cetuximab 500 mg/m^2 + Ixabepilone 80 mg/m^2 group.',\n",
       "             'the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression.': 'the primary trial participants are treated with 1200 mg/m2 of Pemetrexed intravenously every 3 weeks until complete response or disease progression.',\n",
       "             'The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics.': 'The differences between cohorts in the primary trial is twice cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics.',\n",
       "             'the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area.': 'the primary trial uses a set dosage of 2000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area.',\n",
       "             'Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol, and no Mammography.': 'Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 7 mg Estradiol, and no Mammography.',\n",
       "             'All participants in the primary trial are administered with Lapatinib 1500 mg PO QD.': 'All participants in the primary trial are administered with Lapatinib 3000 mg PO QD.',\n",
       "             'In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.': 'In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 200 mg vs 125 mg of oral PD-0332991.'})"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "old2new"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 212,
   "id": "e06e5eaf",
   "metadata": {},
   "outputs": [],
   "source": [
    "new_data = []\n",
    "for h, h_data in data_dict.items():\n",
    "    h, label = h.split('_____')\n",
    "\n",
    "    new_rw = dd()\n",
    "    new_rw.update(h_data)\n",
    "    new_rw['Statement'] = h\n",
    "    new_data.append(new_rw)\n",
    "    if h in old2new:\n",
    "        h_new = old2new[h]\n",
    "        new_rw = dd()\n",
    "        new_rw.update(h_data)\n",
    "        new_rw['Statement'] = h_new\n",
    "        if h_data['Label'] == 'Contradiction':\n",
    "            new_rw['Label'] = 'Entailment'\n",
    "        if h_data['Label'] == 'Entailment':\n",
    "            new_rw['Label'] = 'Contradiction'\n",
    "\n",
    "        new_data.append(new_rw)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 213,
   "id": "ce89e364",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_rows.extend(new_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 214,
   "id": "b63bc6c0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Type</th>\n",
       "      <th>Section_id</th>\n",
       "      <th>Primary_id</th>\n",
       "      <th>Secondary_id</th>\n",
       "      <th>Label</th>\n",
       "      <th>Statement</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT01928186</td>\n",
       "      <td>NCT00684983</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>NCT00093145</td>\n",
       "      <td>NCT00703326</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01097642</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00852930</td>\n",
       "      <td>NCT02308020</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1766</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00213980</td>\n",
       "      <td>NCT02536339</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Adequate blood, kidney, and hepatic function a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1767</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1768</th>\n",
       "      <td>Single</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00181363</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1769</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00834678</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1770</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01004172</td>\n",
       "      <td>NCT00802945</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1771 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            Type      Section_id   Primary_id Secondary_id          Label  \\\n",
       "0     Comparison    Intervention  NCT01928186  NCT00684983  Contradiction   \n",
       "1         Single     Eligibility  NCT00662129          NaN  Contradiction   \n",
       "2     Comparison  Adverse Events  NCT00093145  NCT00703326     Entailment   \n",
       "3         Single     Eligibility  NCT01097642          NaN  Contradiction   \n",
       "4     Comparison    Intervention  NCT00852930  NCT02308020  Contradiction   \n",
       "...          ...             ...          ...          ...            ...   \n",
       "1766  Comparison     Eligibility  NCT00213980  NCT02536339     Entailment   \n",
       "1767      Single         Results  NCT01605396          NaN  Contradiction   \n",
       "1768      Single    Intervention  NCT00181363          NaN     Entailment   \n",
       "1769      Single     Eligibility  NCT00834678          NaN     Entailment   \n",
       "1770  Comparison         Results  NCT01004172  NCT00802945  Contradiction   \n",
       "\n",
       "                                              Statement  \n",
       "0     All the primary trial participants do not rece...  \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...  \n",
       "2     Heart-related adverse events were recorded in ...  \n",
       "3     Adult Patients with histologic confirmation of...  \n",
       "4     Laser Therapy is in each cohort of the primary...  \n",
       "...                                                 ...  \n",
       "1766  Adequate blood, kidney, and hepatic function a...  \n",
       "1767  The Ridaforolimus + Dalotuzumab + Exemestane g...  \n",
       "1768  The only difference between the interventions ...  \n",
       "1769  Patients must have a white blood cell count ab...  \n",
       "1770  the primary trial and the secondary trial both...  \n",
       "\n",
       "[1771 rows x 6 columns]"
      ]
     },
     "execution_count": 214,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(new_data).drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "id": "8a1bf596",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Administration', 'Medication', 'Diagnostic_procedure',\n",
       "       'Lab_value', 'Detailed_description', 'Sign_symptom',\n",
       "       'Biological_structure', 'Disease_disorder',\n",
       "       'Therapeutic_procedure', 'Age', 'Sex', 'Dosage', 'Duration',\n",
       "       'Coreference', 'Severity', 'History', 'Personal_background',\n",
       "       'Date', 'Subject', 'Distance', 'Frequency', 'Clinical_event',\n",
       "       'Outcome', 'Quantitative_concept', 'Activity', 'Family_history',\n",
       "       'Nonbiological_location', 'Volume'], dtype=object)"
      ]
     },
     "execution_count": 115,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities_no_duplicate['label'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "id": "ca61ed0b",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'1',\n",
       " '11 months',\n",
       " '12 weeks',\n",
       " '16 Weeks',\n",
       " '17',\n",
       " '18 months',\n",
       " '2',\n",
       " '2 - 6 months',\n",
       " '2 years',\n",
       " '2.5 months',\n",
       " '200 days',\n",
       " '21 day',\n",
       " '28',\n",
       " '3',\n",
       " '3 months',\n",
       " '3 years',\n",
       " '5',\n",
       " '5 year',\n",
       " '6',\n",
       " '6 months',\n",
       " 'a',\n",
       " 'a month',\n",
       " 'last 6 months',\n",
       " 'less',\n",
       " 'months',\n",
       " 'more',\n",
       " 'more than 7',\n",
       " 'more than a',\n",
       " 'more than a year',\n",
       " 'next 5',\n",
       " 'number of days',\n",
       " 'over 14 weeks',\n",
       " 'over 21 days',\n",
       " 'over 36 hours',\n",
       " 'over 5 years',\n",
       " 'over a',\n",
       " 'over a month',\n",
       " 'over a year',\n",
       " 'over half a year',\n",
       " 'past 2 weeks',\n",
       " 'shorter period',\n",
       " 'time',\n",
       " 'two weeks',\n",
       " 'under a year',\n",
       " 'weeks',\n",
       " 'within',\n",
       " 'year',\n",
       " 'years'}"
      ]
     },
     "execution_count": 116,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Lab Value column\n",
    "set(entities[entities['label'] == 'Duration']['entity'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "6ee66834",
   "metadata": {},
   "outputs": [],
   "source": [
    "map_ = {\n",
    "    'minute': 'hour',\n",
    "    'hour': 'day',\n",
    "    'day': 'week',\n",
    "    'week': 'month',\n",
    "    'month': 'year',\n",
    "    \n",
    "}\n",
    "\n",
    "old2new = dd(str)\n",
    "for text in hypotheses:\n",
    "    new_text = text\n",
    "    to_replace = []\n",
    "    for word, replacement in map_.items():\n",
    "        if f' {word}' in text.lower():\n",
    "            to_replace.append(word)\n",
    "    if len(to_replace) == 0:\n",
    "        continue\n",
    "    for word in to_replace:\n",
    "        new_text = new_text.replace(word, map_[word])\n",
    "        #new_text = re.sub(r'\\b' + re.escape(word) + r'\\b', values_to_perturb[word], new_text, flags=re.IGNORECASE)\n",
    "            \n",
    "    old2new[text] = new_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "edf2e4b4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(str,\n",
       "            {'Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial.': 'Agatha had her 50th birthday last month, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial.',\n",
       "             'The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.': 'The shortest PFS in the Talazoparib group of the primary trial was over a year shorter than the Median PFS for that group.',\n",
       "             'Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.': 'Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 years.',\n",
       "             'Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.': 'Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 years.',\n",
       "             'Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study.': 'Both cohorts the primary trial apply the topical intervention for approximately every 4-6 months every month for a month of the study.',\n",
       "             'At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.': 'At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and yearly 10 hours intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 years.',\n",
       "             'A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial.': 'A patient who underwent T-cell transfer therapy in the past 2 months would be excluded from the primary trial.',\n",
       "             'the primary trial uses a 3 week cycle for SB-715992 administration.': 'the primary trial uses a 3 month cycle for SB-715992 administration.',\n",
       "             'the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks.': 'the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two months.',\n",
       "             'There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.': 'There was over 14 months difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.',\n",
       "             'In order to participate in the primary trial, participants must be aware of where they are, and what day it is.': 'In order to participate in the primary trial, participants must be aware of where they are, and what week it is.',\n",
       "             '59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.': '59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 years.',\n",
       "             'The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once.': 'The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several months, whereas the interventions for the secondary trial are only apllied once.',\n",
       "             'It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours': 'It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 days',\n",
       "             'Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months': 'Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 years',\n",
       "             'The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months.': 'The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 years.',\n",
       "             'Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial.': 'Heavy smokers (more than 5 cigarettes smoked per week) are eligible for the secondary trial and the primary trial.',\n",
       "             'the primary trial participants are given saracatinib PO every single day of the study duration.': 'the primary trial participants are given saracatinib PO every single week of the study duration.',\n",
       "             'Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial.': 'Patients must be doing less than 2 days of physical exercise per month to participate in the primary trial, however, this is not a requirement for the secondary trial.',\n",
       "             'the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study.': 'the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first week of the study.',\n",
       "             'According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg.': 'According to the results of the primary trial the MTD of dasatinib in combination with monthly paclitaxel is approximately is 120 mg.',\n",
       "             ' Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.': ' Patients in the primary trial receive oral pazopanib once daily every week, continuing until disease progression or unacceptable toxicity.',\n",
       "             'All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.': 'All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.',\n",
       "             'Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.': 'Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m¬¨‚â§ as monotherapy once every 21 weeks (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.',\n",
       "             'Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.': 'Candidates for the primary trial must have a bone density scan 1 year prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.',\n",
       "             'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.': 'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 years.',\n",
       "             'Candidates for the primary trial are expected to be capable of holding their breath for half a minute.': 'Candidates for the primary trial are expected to be capable of holding their breath for half a hour.',\n",
       "             'Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month.': 'Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every year and 3 doses of Nab-paclitaxel (Abraxane) per year.',\n",
       "             'The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month.': 'The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one year.',\n",
       "             'the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle.': 'the primary trial participants apply topical imiquimod to cutaneous lesions once daily on weeks for a total of 13 weeks every 28 week cycle.',\n",
       "             \"If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for the next month.\": \"If Hannah has been taking ketoconazole to treat athlete's foot for 6 years, until today, she will not be eligible for the primary trial for the next year.\",\n",
       "             'The longest Time to Disease Progression the primary trial was over 11 months  in the Docetaxel Plus Capecitabine group.': 'The longest Time to Disease Progression the primary trial was over 11 years  in the Docetaxel Plus Capecitabine group.',\n",
       "             'Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months.': 'Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 years or until death, and the median PFS for this group was just under 7 and a half years.',\n",
       "             'Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months.': 'Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 years.',\n",
       "             'In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.': 'In the primary trial There was less than 3 weeks difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.',\n",
       "             'Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort.': 'Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort.',\n",
       "             'The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group': 'The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 years shorter than the Carboplatin group',\n",
       "             'In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. ': 'In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 years after treatment, than cohort 2. ',\n",
       "             'Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.': 'Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive monthly supplementation of cholecalciferol.',\n",
       "             'Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.': 'Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per month for 6 doses.',\n",
       "             'Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial.': 'Females over the age of 18, whose last period was 2 months prior are eligible for the primary trial.',\n",
       "             'None of the subjects in the primary trial are required to injest any pills, whereas both cohorts of the secondary trial must take a weekly tablet.': 'None of the subjects in the primary trial are required to injest any pills, whereas both cohorts of the secondary trial must take a monthly tablet.',\n",
       "             'the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment.': 'the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 months after the start of treatment.',\n",
       "             'The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191.': 'The minimum number of weeks from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191.',\n",
       "             'Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial.': 'Patients must be over the age of 18 and have a life expectancy over 6 years to participate in the primary trial.',\n",
       "             'Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month.': 'Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last year.',\n",
       "             'the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles': 'the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 week cycle, for 2 cycles',\n",
       "             'Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.': 'Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.',\n",
       "             'Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.': 'Spanish women with a heart rate of at least 60 beats per hour are eligible for the primary trial.',\n",
       "             'Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.': 'Arm 1 of the primary trial receive dose-intensive chemotherapy on a month long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.',\n",
       "             '56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.': '56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.',\n",
       "             'Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial.': 'Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 years are excluded from the primary trial.',\n",
       "             'antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial.': 'antibiotics within 10 weeks prior to beginning is acceptable for patients entering the primary trial.',\n",
       "             'The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months.': 'The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 years.',\n",
       "             'the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.': 'the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.',\n",
       "             'A patient who had an oophorectomy in the last month would not be eligible for the primary trial.': 'A patient who had an oophorectomy in the last year would not be eligible for the primary trial.',\n",
       "             'On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.': 'On week 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.',\n",
       "             '30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment.': '30% of the primary trial participants had an increased level of CECs after 3 months of Cediranib Maleate treatment.',\n",
       "             'The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17': 'The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17',\n",
       "             'Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial.': 'Patients with wounds that havent healed within five to eight months are ineligible for the primary trial.',\n",
       "             'At least one participant of the primary trial survived over 200 days without documented disease progression.': 'At least one participant of the primary trial survived over 200 weeks without documented disease progression.',\n",
       "             'Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial': 'Female patients over 6 years pregnant cannot take part in either the secondary trial or the primary trial',\n",
       "             'Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks.': 'Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 months.',\n",
       "             'The median TTP in cohort one of the primary trial is just under 27 months.': 'The median TTP in cohort one of the primary trial is just under 27 years.',\n",
       "             'Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.': 'Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 months before study entry are eligible for the primary trial but excluded from the secondary trial.',\n",
       "             'The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, no physical activity is explicitly required for the secondary trial.': 'The intervention for the primary trial requires participants to exercise for 12 months while wearing a fitbit, no physical activity is explicitly required for the secondary trial.',\n",
       "             'Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.': 'Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 months.',\n",
       "             'the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression.': 'the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 months until complete response or disease progression.',\n",
       "             'Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment.': 'Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment.',\n",
       "             'Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial.': 'Candidates must have a life expectancy exceeding 3 years to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial.',\n",
       "             'Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial.': 'Mark suffered Refractory ventricular fibrillation twice in the last year he is therefore excluded from the primary trial.',\n",
       "             'ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial.': 'ECOG < 2 and a life expectancy over 12 months are necessary to participate in the primary trial.',\n",
       "             'the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks.': 'the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 months.',\n",
       "             'the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.': 'the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 years longer than patients administered with Lapatinib Plus Capecitabine.',\n",
       "             'The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial.': 'The Median Overall Survival for cohort 1 patients was 44 weeks longer than for patients in cohort 2 of the primary trial.',\n",
       "             'Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs.': 'Patients receiving intervention 1 of the primary trial undergo a 21 week treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs.',\n",
       "             'The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion.': 'The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion.',\n",
       "             'By week 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.': 'By month 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.',\n",
       "             'The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months.': 'The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 years.',\n",
       "             'The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.': 'The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 months.',\n",
       "             'Sharone had a hip replacement 3 weeks prior, she is not elgible for the primary trial.': 'Sharone had a hip replacement 3 months prior, she is not elgible for the primary trial.',\n",
       "             'A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.': 'A patient was treated with Pertuzumab for 6 years, and this treatment was discontinued 2 years prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.',\n",
       "             'At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months.': 'At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 years.',\n",
       "             'Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study.': 'Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every week of the study.',\n",
       "             'The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.': 'The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.'})"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "old2new"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 217,
   "id": "532f48e0",
   "metadata": {},
   "outputs": [],
   "source": [
    "new_data = []\n",
    "for h, h_data in data_dict.items():\n",
    "    h, label = h.split('_____')\n",
    "\n",
    "    new_rw = dd()\n",
    "    new_rw.update(h_data)\n",
    "    new_rw['Statement'] = h\n",
    "    new_data.append(new_rw)\n",
    "    if h in old2new:\n",
    "        h_new = old2new[h]\n",
    "        new_rw = dd()\n",
    "        new_rw.update(h_data)\n",
    "        new_rw['Statement'] = h_new\n",
    "        if h_data['Label'] == 'Contradiction':\n",
    "            new_rw['Label'] = 'Entailment'\n",
    "        if h_data['Label'] == 'Entailment':\n",
    "            new_rw['Label'] = 'Contradiction'\n",
    "\n",
    "        new_data.append(new_rw)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 218,
   "id": "c296495c",
   "metadata": {},
   "outputs": [],
   "source": [
    "all_rows.extend(new_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 219,
   "id": "37142946",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Type</th>\n",
       "      <th>Section_id</th>\n",
       "      <th>Primary_id</th>\n",
       "      <th>Secondary_id</th>\n",
       "      <th>Label</th>\n",
       "      <th>Statement</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT01928186</td>\n",
       "      <td>NCT00684983</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>NCT00093145</td>\n",
       "      <td>NCT00703326</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01097642</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00852930</td>\n",
       "      <td>NCT02308020</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1882</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1883</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1884</th>\n",
       "      <td>Single</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00181363</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The only difference between the interventions ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1885</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00834678</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Patients must have a white blood cell count ab...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1886</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01004172</td>\n",
       "      <td>NCT00802945</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>the primary trial and the secondary trial both...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1887 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            Type      Section_id   Primary_id Secondary_id          Label  \\\n",
       "0     Comparison    Intervention  NCT01928186  NCT00684983  Contradiction   \n",
       "1         Single     Eligibility  NCT00662129          NaN  Contradiction   \n",
       "2     Comparison  Adverse Events  NCT00093145  NCT00703326     Entailment   \n",
       "3         Single     Eligibility  NCT01097642          NaN  Contradiction   \n",
       "4     Comparison    Intervention  NCT00852930  NCT02308020  Contradiction   \n",
       "...          ...             ...          ...          ...            ...   \n",
       "1882      Single         Results  NCT01605396          NaN  Contradiction   \n",
       "1883      Single         Results  NCT01605396          NaN     Entailment   \n",
       "1884      Single    Intervention  NCT00181363          NaN     Entailment   \n",
       "1885      Single     Eligibility  NCT00834678          NaN     Entailment   \n",
       "1886  Comparison         Results  NCT01004172  NCT00802945  Contradiction   \n",
       "\n",
       "                                              Statement  \n",
       "0     All the primary trial participants do not rece...  \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...  \n",
       "2     Heart-related adverse events were recorded in ...  \n",
       "3     Adult Patients with histologic confirmation of...  \n",
       "4     Laser Therapy is in each cohort of the primary...  \n",
       "...                                                 ...  \n",
       "1882  The Ridaforolimus + Dalotuzumab + Exemestane g...  \n",
       "1883  The Ridaforolimus + Dalotuzumab + Exemestane g...  \n",
       "1884  The only difference between the interventions ...  \n",
       "1885  Patients must have a white blood cell count ab...  \n",
       "1886  the primary trial and the secondary trial both...  \n",
       "\n",
       "[1887 rows x 6 columns]"
      ]
     },
     "execution_count": 219,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(new_data).drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "id": "022d249b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Administration', 'Medication', 'Diagnostic_procedure',\n",
       "       'Lab_value', 'Detailed_description', 'Sign_symptom',\n",
       "       'Biological_structure', 'Disease_disorder',\n",
       "       'Therapeutic_procedure', 'Age', 'Sex', 'Dosage', 'Duration',\n",
       "       'Coreference', 'Severity', 'History', 'Personal_background',\n",
       "       'Date', 'Subject', 'Distance', 'Frequency', 'Clinical_event',\n",
       "       'Outcome', 'Quantitative_concept', 'Activity', 'Family_history',\n",
       "       'Nonbiological_location', 'Volume'], dtype=object)"
      ]
     },
     "execution_count": 139,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "entities_no_duplicate['label'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 144,
   "id": "e620695d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'237 ml'}"
      ]
     },
     "execution_count": 144,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Lab Value column\n",
    "set(entities[entities['label'] == 'Volume']['entity'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 223,
   "id": "56c5d02f",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Type</th>\n",
       "      <th>Section_id</th>\n",
       "      <th>Primary_id</th>\n",
       "      <th>Secondary_id</th>\n",
       "      <th>Label</th>\n",
       "      <th>Statement</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT01928186</td>\n",
       "      <td>NCT00684983</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>All the primary trial participants do not rece...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT00662129</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Patients with Platelet count over 100,000/mm¬¨...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Adverse Events</td>\n",
       "      <td>NCT00093145</td>\n",
       "      <td>NCT00703326</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>Heart-related adverse events were recorded in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01097642</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Adult Patients with histologic confirmation of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Comparison</td>\n",
       "      <td>Intervention</td>\n",
       "      <td>NCT00852930</td>\n",
       "      <td>NCT02308020</td>\n",
       "      <td>Contradiction</td>\n",
       "      <td>Laser Therapy is in each cohort of the primary...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9218</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT00558272</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The biggest change in Change From Baseline in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9224</th>\n",
       "      <td>Single</td>\n",
       "      <td>Eligibility</td>\n",
       "      <td>NCT01094184</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>A patient who had a Joint injection in the las...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9236</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT00240071</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>At least one participant of the primary trial ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9250</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT00708214</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>All Participants with disease progression (Aft...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9256</th>\n",
       "      <td>Single</td>\n",
       "      <td>Results</td>\n",
       "      <td>NCT01605396</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Entailment</td>\n",
       "      <td>The Ridaforolimus + Dalotuzumab + Exemestane g...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2460 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            Type      Section_id   Primary_id Secondary_id          Label  \\\n",
       "0     Comparison    Intervention  NCT01928186  NCT00684983  Contradiction   \n",
       "1         Single     Eligibility  NCT00662129          NaN  Contradiction   \n",
       "2     Comparison  Adverse Events  NCT00093145  NCT00703326     Entailment   \n",
       "3         Single     Eligibility  NCT01097642          NaN  Contradiction   \n",
       "4     Comparison    Intervention  NCT00852930  NCT02308020  Contradiction   \n",
       "...          ...             ...          ...          ...            ...   \n",
       "9218      Single         Results  NCT00558272          NaN     Entailment   \n",
       "9224      Single     Eligibility  NCT01094184          NaN     Entailment   \n",
       "9236      Single         Results  NCT00240071          NaN     Entailment   \n",
       "9250      Single         Results  NCT00708214          NaN     Entailment   \n",
       "9256      Single         Results  NCT01605396          NaN     Entailment   \n",
       "\n",
       "                                              Statement  \n",
       "0     All the primary trial participants do not rece...  \n",
       "1     Patients with Platelet count over 100,000/mm¬¨...  \n",
       "2     Heart-related adverse events were recorded in ...  \n",
       "3     Adult Patients with histologic confirmation of...  \n",
       "4     Laser Therapy is in each cohort of the primary...  \n",
       "...                                                 ...  \n",
       "9218  The biggest change in Change From Baseline in ...  \n",
       "9224  A patient who had a Joint injection in the las...  \n",
       "9236  At least one participant of the primary trial ...  \n",
       "9250  All Participants with disease progression (Aft...  \n",
       "9256  The Ridaforolimus + Dalotuzumab + Exemestane g...  \n",
       "\n",
       "[2460 rows x 6 columns]"
      ]
     },
     "execution_count": 223,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(all_rows).drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 225,
   "id": "ad9f5de0",
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.DataFrame(all_rows).drop_duplicates().to_json('dataset_5.json', orient='index')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "5e0db013",
   "metadata": {},
   "outputs": [],
   "source": [
    "to_verify = {\n",
    "    'Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial': 'Adele is an 95 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial',\n",
    "    'The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.': 'The shortest PFS in the Talazoparib group of the primary trial was under a month shorter than the Median PFS for that group.',\n",
    "    'Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.': 'Most patients in the Letrozole group of the primary trial had a increased Bone Mineral Density of the Lumbar Spine after 24 months.',\n",
    "    'A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial.': 'A patient who underwent T-cell transfer therapy in the past 3 weeks would be excluded from the primary trial.',\n",
    "    'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.': 'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 years.',\n",
    "\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "99d632be",
   "metadata": {},
   "outputs": [],
   "source": [
    "#to_verify = {h.lower():p for h, p in to_verify.items()}\n",
    "avail = list(to_verify.keys())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "id": "92fcbe25",
   "metadata": {},
   "outputs": [],
   "source": [
    "data_expanded = []\n",
    "for _id, value in data.items():\n",
    "    statement = value[\"Statement\"]\n",
    "    if statement in avail:\n",
    "        temp = {}\n",
    "        temp[\"id\"] = _id\n",
    "        p_nctid = value[\"Primary_id\"]\n",
    "        s_nctid = value.get(\"Secondary_id\")\n",
    "        section_id = value[\"Section_id\"]\n",
    "\n",
    "        primary_evidence = files_data[p_nctid][section_id]\n",
    "        temp[\"statement\"] = statement\n",
    "        sentence = 'Primary Evidence: ' + ''.join(primary_evidence)\n",
    "        temp[\"label\"] = value[\"Label\"]\n",
    "\n",
    "        if s_nctid is not None:\n",
    "            secondary_evidence = files_data[s_nctid][section_id]\n",
    "            sentence += 'Secondary Evidence' + ''.join(secondary_evidence)\n",
    "        temp['premise'] = sentence\n",
    "        temp['perturbation'] = to_verify[statement]\n",
    "        data_expanded.append(temp)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "a4c23cbc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'id': '8765009d-ffc4-4395-ab7a-11ecdfd43a40',\n",
       "  'statement': 'Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial',\n",
       "  'label': 'Entailment',\n",
       "  'premise': \"Primary Evidence: Inclusion Criteria:  Must be female with histologically confirmed breast cancer  Stage II-IV disease  ER and/or PR positive  ECOG Performance Status 0-1  Tumor must be present following core needle biopsy as determined by physical exam or radiographic evaluation.  Postmenopausal  No prior treatment for current breast cancer. No other active malignancy is allowed.Adequately treated basal cell, squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years is permitted. Biphosphonates and palliative radiation for bone metastasis is permitted while on study.  Hormone replacement therapy must be discontinued. It is not permitted during the time on study.Exclusion Criteria:  Known history of aspirin or NSAID induced asthma, urticaria or allergic reactions; or allergy to sulfonamides severe enough in nature to require emergency room treatment or hospitalization.  History of myocardial infarction or other thrombotic events.  Inflammatory breast cancer (edema or ulceration of the skin of the breast).  Significant renal dysfunction (serum creatinine > 1.5 x upper limit of normal).  Significant hepatic dysfunction (serum bilirubin > 1.5 x upper limit of normal or AST, ALT > 3 x upper limit of normal)  ANC <1.5, platelets <100,000 K/uL, and hemoglobin < 9 g/dL.  Use of other COX-2 inhibitors such as rofecoxib (Vioxx®, aspirin, trisalicylate (Trilisate®), is not permitted during the time on study. No washout period is required. Baby aspirin, 81 mg po daily, is permitted.  Use of NSAID's such as ibuprofen (Advil® or Motrin®), naproxyn (Aleve® Naprosyn®, or Anaprox®), etodolac (Lodine®), oxaprozin (Daypro®), difusanil (Dolobid®), nabumetone (Relafin®), or tolmetin (Tolectin®) is not permitted during the time on study.\",\n",
       "  'perturbation': 'Adele is an 95 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial'},\n",
       " {'id': 'ccc5362a-33d0-4f1b-be46-d31729ba9194',\n",
       "  'statement': 'The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.',\n",
       "  'label': 'Entailment',\n",
       "  'premise': \"Primary Evidence: Outcome Measurement:   Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment  IRF assessed PFS was defined as time (in months) from randomization until the date of first documented radiologic progressive disease per response evaluation criteria in solid tumors (RECIST) version 1.1 or death from any cause, whichever occurs first. As per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target lesion measurements, compared to the smallest sum on study (including baseline), the absolute increase in the sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal progression of non-target lesions, evaluated as a whole, such that it is clear that treatment has failed and disease is progressing, regardless of the status of the target lesions; 3) and/or appearance of one or more new lesions. The analysis was performed by Kaplan-Meier method.  Time frame: Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)Results 1:   Arm/Group Title: Talazoparib  Arm/Group Description: Participants received talazoparib 1 mg, orally, once daily until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or sponsor's decision to terminate the trial (up to a maximum of 70.2 months). One cycle was of 21 days.  Overall Number of Participants Analyzed: 287  Median (95% Confidence Interval)  Unit of Measure: months  8.6        (7.2 to 9.3)Results 2:   Arm/Group Title: Physician's Choice Treatment  Arm/Group Description: Participants received 1 of the following drugs in specified regimens, as per the physician's choice: 1) capecitabine 1250 mg/m^2 orally twice daily on Day 1 to 14 in each cycle; 2) eribulin mesylate 1.4 mg/m^2 (equivalent to eribulin 1.23 mg/ m^2), as 2 to 5 minute IV infusion on Day 1 and 8 in each cycle; 3) gemcitabine 1250 mg/m^2 as 30-minute IV infusion on Day 1 and 8 in each cycle; 4) vinorelbine 30 mg/m^2 as 6 to 10 minute IV infusion on Day 1, 8, and 15 in each cycle; until radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or Sponsor's decision to terminate the trial (up to a maximum of 45.3 months). One cycle was of 21 days.  Overall Number of Participants Analyzed: 144  Median (95% Confidence Interval)  Unit of Measure: months  5.6        (4.2 to 6.7)\",\n",
       "  'perturbation': 'The shortest PFS in the Talazoparib group of the primary trial was under a month shorter than the Median PFS for that group.'},\n",
       " {'id': '2744cc0a-86e9-4764-ae1c-f10f635dc283',\n",
       "  'statement': 'Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.',\n",
       "  'label': 'Entailment',\n",
       "  'premise': 'Primary Evidence: Outcome Measurement:   Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)  Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader.  Time frame: Baseline, 24 monthsResults 1:   Arm/Group Title: Letrozole  Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years  Overall Number of Participants Analyzed: 63  Median (Full Range)  Unit of Measure: Percent Change  -4.63        (-14.21 to 4.32)Results 2:   Arm/Group Title: Tam-Let  Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.  Overall Number of Participants Analyzed: 68  Median (Full Range)  Unit of Measure: Percent Change  0.37        (-6.98 to 15.21)',\n",
       "  'perturbation': 'Most patients in the Letrozole group of the primary trial had a increased Bone Mineral Density of the Lumbar Spine after 24 months.'},\n",
       " {'id': 'a529e364-2da7-4067-acb6-9fb2f0adf08b',\n",
       "  'statement': 'A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial.',\n",
       "  'label': 'Entailment',\n",
       "  'premise': \"Primary Evidence: Inclusion Criteria:  Biopsy-proven breast cancer, metastatic (persistent or recurrent).  Failed 1 line of therapy (endocrine or chemotherapy) for metastatic disease.  Min. 3 distinct metastatic sites, at least one measurable lesion which is at least 1 cm or larger in largest diameter.  Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia):  major surgery;  radiotherapy;  chemotherapy (  6 weeks since therapy if a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab);  immunotherapy;  biotherapy/targeted therapies.  >18 years of age.  Life expectancy >6 months.  Eastern Cooperative Oncology Group (ECOG) status 0 or 1.  Adequate organ function including:  Hemoglobin 10.0g/dL, absolute neutrophil count (ANC) 1,500/mm3, and platelets 100,000/mm3.  Hepatic: Serum total bilirubin 1.5x upper limit of normal (ULN) (Patients with Gilbert's Disease may be included if total bilirubin is 3.0mg/dL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) 2.5xULN. If patient has known liver metastases, ALT and/or AST 5xULN are allowed.  Renal: creatinine clearance 60mL/min.  Prothrombin (PT) and partial thromboplastin times (PTT) <ULN.  Negative for hepatitis viruses B and C unless consistent with prior vaccination or prior infection with full recovery.  Patients of childbearing potential must agree to use effective contraception while on study, and for 3 months after last treatment.  Understand and sign written informed consent document. No consent by durable power of attorney.Exclusion Criteria:  Second malignancy - unless following curative intent therapy, has been disease free for 2 years with probability of recurrence <5%. Curatively treated early-stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are allowed.  Concurrent cancer therapy.  Uncontrolled central nervous system (CNS) metastases, meningeal carcinomatosis, malignant seizures, or disease that causes or threatens neurologic compromise (e.g. unstable vertebral metastases).  History of ascites or pleural effusions, unless successfully treated.  Organ transplant, including allogeneic bone marrow transplant.  Immunosuppressive therapy including:  Systemic corticosteroid therapy, including replacement therapy for hypoadrenalism. Inhaled or topical corticosteroids are allowed (if therapy is <5 days and is limited to systemic steroids as antiemetics);  Cyclosporine A, tacrolimus, or sirolimus.  Investigational agents within 4 weeks prior to study enrollment (  6 weeks if treatment was long-acting agent such as monoclonal antibody).  Significant or uncontrolled medical illness, e.g. congestive heart failure (CHF), myocardial infarction, symptomatic coronary artery disease, significant ventricular arrhythmias within the last 6 months, or significant pulmonary dysfunction. Patients with remote history of asthma or active mild asthma may participate.  Active infection, including unexplained fever (>38.5°C).  Systemic autoimmune disease (e.g. systemic lupus erythematosus, active rheumatoid arthritis).  Known allergy to any component of GC1008.  Active thrombophlebitis, thromboembolism, hypercoagulability states, bleeding, or anti-coagulation therapy (including anti platelet agents i.e. aspirin, clopidogrel, ticlopidine, dipyridamole, other agents inducing long-acting platelet dysfunction). Patients with history of deep venous thrombosis are allowed if treated, completely resolved, and no treatment for >4months.  Calcium >11.0mg/dL (2.75mmol/L) unresponsive or uncontrolled in response to standard therapy (e.g. bisphosphonates).  Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems, including, but not limited to:  Other serious non-malignancy-associated conditions that may be expected to limit life expectancy or significantly increase the risk of SAEs;  Conditions, psychiatric, substance abuse, or other, that, in the opinion of the Investigator, would preclude informed consent, consistent follow-up, or compliance with any aspect of the study;  Pregnant or nursing women.\",\n",
       "  'perturbation': 'A patient who underwent T-cell transfer therapy in the past 3 weeks would be excluded from the primary trial.'},\n",
       " {'id': '45e6b4b6-ca31-4318-936e-5b27cbca47a2',\n",
       "  'statement': 'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.',\n",
       "  'label': 'Entailment',\n",
       "  'premise': 'Primary Evidence: Outcome Measurement:   Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3)  Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. V3 was calculated by subtracting the total MRI FTV measured (i.e. the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline. For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests.  Time frame: up to 3 months from start of treatmentResults 1:   Arm/Group Title: Letrozole + MRI  Arm/Group Description: Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day. Patients will have a bilateral MRI for disease evaluation at months 3 and 6.  Overall Number of Participants Analyzed: 68  Mean (95% Confidence Interval)  Unit of Measure: cubic centimeters  -1.93        (-2.87 to -0.98)',\n",
       "  'perturbation': 'One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 years.'}]"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_expanded"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "76525025",
   "metadata": {},
   "outputs": [],
   "source": [
    "json.dump({'samples': data_expanded}, open('numerical_perturbations.json', 'w+'), indent=4)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a10828c5",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:nlct]",
   "language": "python",
   "name": "conda-env-nlct-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
